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1 Summary  
1.1 Abstract 
Oxidative damage of proteins, lipids, RNA and DNA is the source of many diseases, which 
can be prevented by accurate repair machineries. Besides aging and cancer, oxidative DNA 
damage has been linked to neurodegenerative diseases. One of the most frequent oxidative 
DNA lesion is 7,8-dihydro-8-oxoguanine (8-oxo-G). During DNA replication, this lesion is 
often mispaired with adenosine (A) and thereby bears the risk of G:C→T:A transversion 
mutations. Before DNA replication, 8-oxoguanine glycosylase 1 (OGG1) initiated base 
excision repair (BER) needs to act on C:8-oxo-G and restore accurate G:C basepair. In case 8-
oxo-G becomes a substrate for DNA replication, it is the glycosylase MutY homolog (MutYH) 
and DNA polymerase (Pol) λ that will repair the newly generated, mutagenic A:8-oxo-G. 
Among other regulators, the Mcl-1 ubiquitin ligase E3 (Mule) controls these processes by 
ubiquitinating Pol λ and sending it for proteasomal degradation. So far only little is known 
about the physiological importance of Mule in regulation of MutYH/Pol λ mediated BER. 
Here, the effects of mutated Mule on 8-oxo-G repair capacity in patients suffering from X-
linked intellectual disability (XLID) were explored. This work addressed (i) the differences in 
protein amounts of Mule and A:8-oxo-G repair factors, (ii) changes in their presence in 
different cellular compartments, as well as (iii) the capacity to repair A:8-oxo-G mispairs and 
(iv) overall bypass accuracy of 8-oxo-G damage. The results show that in relation to a healthy 
individual, MutYH and Pol λ protein levels are specifically changed in XLID patients with 
mutated Mule. These changes were characteristically reflected in the subcellular fractions and 
reveal a functional link between MutYH and Pol λ. A DNA polymerase assay and a novel 
MutYH glycoslase assay displayed the different repair capacities in XLID patient cells with 
affected Pol λ and MutYH levels. Namely the reduction in MutYH or Pol λ levels 
corresponded to decreased removal of mispaired A or increased inaccurate incorporation of 
dATP opposite 8-oxo-G, respectively. After the Mule knock-down in XLID cells, protein 
levels of both MutYH and Pol λ could be restored to a certain degree, indicating a direct 
impact of mutated Mule on these two proteins. Further, also the accurate A:8-oxo-G repair 
was ameliorated. These findings support a causative effect of mutated Mule in the 
development of neurodegeneration, demonstrated on XLID and a deficient BER of oxidative 
DNA lesions. 
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1.2 Zusammenfassung  
Oxidative Schädigung von Proteinen, Lipiden, RNA und DNA sind die Quellen vieler 
Erkrankungen, die durch intakte Reparaturmechanismen verhindert werden können. 
Oxidative DNA Schäden werden, neben Alterung und Krebs, mit neurodegenerativen 
Erkrankungen in Verbindung gebracht. Eine der häufigsten oxidativen DNA Schäden ist 7,8-
dihydro-8-oxoguanin (8-oxo-G), welches falsche Basenpaarung mit Adenosin (A) eingeht und 
dadurch das Risiko von G:C→T:A Transversionsmutationen birgt. Bevor die DNA 
Replikation stattfindet, stellt die 8-oxoguanin Glykosylase 1 (OGG1) in der 
Basenexzisionreparatur (BER) korrekte G:C Basenpaare wieder her. Nach der Replikation 
sind es MutY Homolog (MutYH) und DNA polymerase λ (Pol λ), die das mutagene A:8-oxo-
G reparieren. Neben anderen Regulatoren kontrolliert die Mcl1 Ubiquitinligase E3 (Mule) 
diese Vorgänge durch Ubiquitinierung und Abbau von Pol λ. Um die physiologische 
Bedeutung der MutYH/Pol λ vermittelten BER zu erläutern, wurden die Auswirkungen 
mutierten Mules in Patienten mit X-assoziierter mentaler Behinderung (XLID) untersucht. 
Der Fokus dieser Arbeit liegt auf der Auswirkung auf (i) die Proteinmengen von Mule und 
A:8-oxo-G Reparaturfaktoren, (ii) ihre Gegenwart in verschiedenen Zellkompartimenten wie 
auch (iii) die veränderte Reparaturkapazität von A:8-oxo-G und (iv) korrekte Handhabung 
der 8-oxo-G Läsion. Die Resultate zeigen, dass die Proteinmengen von MutYH und Pol λ im 
Vergleich mit einem gesunden Individuum in den Zellen von XLID-Patienten mit mutiertem 
Mule verändert sind. Die subzellulären Fraktionen weisen ebenfalls Abweichungen auf, was 
auf einen funktionellen Zusammenhang zwischen MutYH und Pol λ deutet. Ein neu 
entwickelter MutYH Glykosylase und ein DNA Polymerase Assay zeigen die verschiedenen 
Reparatureigenschaften in vitro: Erniedrigte Proteinmengen von MutYH oder Pol λ 
korrespondieren mit erniedrigter Beseitigung von falsch-gepaartem A oder gesteigerter 
fehlerhafter Einfügung von A gegenüber 8-oxo-G. Nach dem Knock-down von Mule stiegen 
die Proteinmengen von MutYH and Pol λ teilweise an, was auf einen direkten Einfluss des 
mutierten Mule auf die BER von 8-oxo-G hinweist. Des Weiteren verbesserte sich auch die 
korrekte Reparatur von A:8-oxo-G. Diese Ergebnisse unterstützen einen ursächlichen 
Zusammenhang zwischen mutiertem Mule und der Entstehung neurodegenerativer 
Erkrankungen. 
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2 Introduction 
2.1 Oxidative DNA damage 
The dependency of living organisms on oxygen has several drawbacks and as such requires 
control mechanisms to overcome them. One attribute of oxygen especially relevant for the 
integrity of genetic information is the potential to react with its building blocks. Whereas 
proteins, lipids or RNA can be replaced when oxidized, DNA cannot 2. Damage to the DNA 
can interfere with various processes, such as transcription and replication, and induce 
mutations. Counteracting DNA damage in the nucleus as well as in the mitochondria is 
therefore crucial to prevent cellular malfunctions and their consequences, such as 
developmental impairments, degeneration or cancer 3. 
  
Figure 1. ROS production and neutralization in the cell.  
(A) Several endogenous and exogenous substances contribute to the generation and 
resolution of ROS. (B) Pathways of ROS production and clearance. GSH, glutathione; GSSG, 
glutathione disulfide. (C) Mechanisms of redox homeostasis. Balance between ROS 
production and various types of scavengers. The steady-state levels of ROS are determined 
by the rate of ROS production and their clearance by scavenging mechanisms. Certain 
antioxidative enzymes including superoxide dismutase (SOD), glutathione peroxidase, 
catalase, and thioredoxin are potent ROS scavengers but occur in cells only at relatively low 
concentrations. The same is true for nonenzymic antioxidants. Amino acids and proteins are 
also ROS scavengers. Amino acids are less effective than the classical antioxidants on a 
molecular basis, but their cumulative intracellular concentration is higher. (From and 
modified after Wulf Dröge. (2002) Free Radicals in the Physiological Control of Cell 
Function. Physiological Reviews and O. Firuzi, R. Miri, M. Tavakkoli and L. Saso. (2011) 
Antioxidant Therapy: Current Status and Future Prospects. Current Medicinal Chemistry) 
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Oxidative DNA damage can be induced by 
different sources: (i) endogenous products of 
cellular metabolism and spontaneous oxidative 
reactions, as well as (ii) exogenous agents 
ranging from UV-light to irradiation, or toxins 
and pollutants (Figure 1A). Overall, every 
mammalian cell accumulates on average 20'000 
endogenous DNA lesions per day 4. In a healthy 
resting cell, 2% of the absorbed oxygen is 
transformed into reactive oxygen species (ROS) 5 
leading to endogenous oxidative DNA lesions. 
Those result predominantly from mitochondrial 
oxidative metabolism, activated inflammatory cells, or enzymes which produce ROS such as 
superoxide anions, hydrogen peroxide and hydroxyl radicals (Figure 1B) 6,7. Besides 
damaging cellular components such as DNA, ROS are involved in the regulation of 
proliferation, gene expression and signaling 8. Several enzymatic and non-enzymatic cascades 
evolved to regulate cellular ROS levels. These include enzymatic antioxidants, such as 
superoxide dismutase, glutathione peroxidase and catalase, and non-enzymatic antioxidants, 
for example β-carotene (provitamin A), vitamin E (α-Tocopherol) and C (Ascorbic acid), and 
glutathione (Figure 1C) 9.  
One of the most abundant and best-studied oxidative DNA lesions with mutational capacity 
is 7,8-dihydro-8-oxoguanine (8-oxo-G). This lesion frequently arises due to the low redox 
potential of guanine. It carries a hydrogen atom on the nitrogen at position 7 and an oxygen 
on the carbon at position 8 (Figure 2) 10. Replicative DNA polymerases (Pols) can bypass 8-
oxo-G lesion in an error-prone manner by incorporating incorrect dATP in trans 
conformation opposite the lesion in syn conformation (Figure 3) 11. The created mispair 
escapes proofreading activity of replicative Pols δ and ε, thus persisting in the DNA after 
completion of replication. If A:8-
oxo-G mispairs are not repaired 
before the next round of 
replication, G:C→T:A 
transversion mutations will 
arise. These mutations are 
frequently found in many 
cancer types such as lung, breast, 
ovarian, gastric, and colorectal 
cancers 12. While normal cells 
encounter approximately 1'000-
2'000 8-oxo-G lesions per day, 
the number of these lesions can 
reach up to 100'000 in cancer 
cells 13. In addition to 8-oxo-G, 
many other lesions are induced 
by oxidizing agents, including: 
abasic sites, bulky base damages, 
single-strand breaks, protein-
DNA adducts and DNA 
crosslinks (Table 1) 14.  
  
Figure 2. Structure of 7,8-dihydro-8-
oxoguanine (8-oxo-G) damage.  
(From Sheila S. David, Valerie L. 
O’Shea, and Sucharita Kundu. (2007) 
Base excision repair of oxidative DNA 
damage. Nature) 
 
  
Figure 3. Structures of 8-oxo-G containing base pairs.  
The structures of the natural base pairs G:C and T:A are 
compared with those of C:8-oxo-G and A:8-oxo-G. 8-oxo-G 
differs from G by an additional oxygen at position C8 and a 
hydrogen at N7. This subtle change allows 8-oxo-G to base-
pair easily with either C or A. (From Sheila S. David, 
Valerie L. O’Shea, and Sucharita Kundu. (2007) Base 
excision repair of oxidative DNA damage. Nature) 
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Once DNA is damaged, cells can react in several different ways. Upon registry of the damage 
cell cycle arrest can occur, enabling initiation of DNA repair or apoptosis. The latter results in 
elimination of defective cells and prevents tissue malfunction or development of cancer. On 
the other side, the cell can also enter senescence and restrain from further replication. If 
damage accumulates, the cell will either gradually loose its function and age, or develop 
oncogenic potential 15. To counteract onset of these events several repair pathways have 
developed 16,17. Depending on the type of DNA damage, specific DNA repair pathways will 
be used (Table 1). The importance of efficient and faithful repair of different oxidative DNA 
lesions is demonstrated by numerous findings showing that not only cancer but also 
neurodegenerative, pulmonary and cardiovascular diseases as well as ageing correlate with 
ROS and 8-oxo-G levels 2,18.  
 
Table 1. Classical and atypical forms of oxidative DNA damage and associated DNA repair 
pathways.  
BER/NER: base/nucleotide excision repair, ICR: interstrand crosslink repair, RFR: replication 
fork restart. (Modified after Brian R. Berquist, David M. Wilson III. (2012) Pathways for 
repairing and tolerating the spectrum of oxidative DNA lesions . Cancer Letters) 
 
Type of lesion Lesion Repair Pathway 
non-bulky base 
modifications 
7,8-dihydro-8-oxo-guanine (8-oxo-G) 
BER 
2,6-diamino-4-hydroxy-5-
formamidopyrimidine (Fapy-G) 
7,8-dihydro-8-oxoadenine 
4,6-diamino-5- formamidopyrimidine (Fapy-
A) 
cytosine glycol, uracil glycol, 5-
hydroxycytosine, 5-hdroxyuracil 
thymine glycol, 5,6-dihydroxythymine, 5-
hydroxymethyluracil, 5-formyluracil 
apurinic/apyrimidinic site, 2-
deoxyribonolactone, 2-deoxypentos-4-ulose, 
single strand breaks (SSBs) 
bulky base 
modifications 
8,5'-cyclo-2-deoxynucleosides 
NER etheno-adducts intrastrand crosslinks 
protein-DNA crosslinks 
interstrand 
crosslinks replication blocking lesions 
ICR 
RFR 
2.1.1 Base excision repair (BER) - a pathway for removal of small base lesions 
2.1.1.1 BER overview 
Base excision repair (BER) is one of several different pathways to efficiently repair damaged 
DNA (Figure 4). BER acts on DNA base lesions generated by alkylation, oxidation, ring 
saturation or deamination 19,20. Depending on the number of newly incorporated nucleotides 
(nt), BER divides in two sub-pathways: short-patch (SP-BER) and long-patch BER (LP-BER) 21. 
SP-BER is characterized by incorporation of 1nt (Figure 4A), while in LP-BER a newly 
synthetized patch of 2 to 12nt is generated (Figure 4B). The BER pathway is generally 
initiated by DNA glycosylases, enzymes that recognize the damaged base and incise the N-
  6 
glycosylic bond between the 2'-deoxyribose and the base. In humans, 11 different DNA 
glycosylases have been identified so far 22. If the DNA glycosylase is monofunctional, upon 
removal of the damaged base it leaves behind an apurinic/apyrimidinic (AP). In the next step 
the major 5' AP endonuclease, apurinic/apyrimidinic endonuclease 1 (APE1) generates a 
single nucleotide gap (1nt-gap) with a 3' hydroxyl (3'OH) end and a 5' deoxyribose phosphate 
(5'dRp) terminus 23. Pol β, the primary BER Pol which possesses dRp lyase activity, removes 
the 5'dRp moiety and incorporates 1nt. Bifunctional DNA glycosylases on the other hand, 
possess also a β lyase activity. They excise the damaged base and cut the sugar phosphate 
backbone, generating a 3'terminal sugar phosphate (3'ddR5P) and a 5' phosphate residue. The 
3'ddR5P moiety is processed by APE1 and a 1nt-gap filled by Pol β.  
NEIL1 belongs to the DNA glycosylases of the endonuclease VIII like (Nei)-proteins (NEIL) 
and has been shown to remove 8-oxo-G from the genome when paired to G, A or C 24. Its 
main targets in a physiological environment are 4,6-diamino-5- formamidopyrimidine 
(FapyA) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) 25, and it even works 
on bubble structures 26. In contrast to monofunctional and bifunctional glycosylases, NEIL 
glycosylases are capable of β/δ elimination leaving behind 3'- and 5'-phosphate residues, 
after lesion removal and cleavage of the sugar backbone. The 3'-phosphate is then processed 
by polynucleotide kinase (PNK) to obtain a 3'OH end so that BER can be continued by Pol β 
  
Figure 4. Repair of a damaged DNA base via SP-BER (A) and LP-BER (B).  
(A) on the left, a monofunctional glycosylase removes DNA lesion and generates an AP 
site, processed by APE1, which leaves behind a 1nt-gap with a free 3'OH end and a 5'dRP 
terminus. In the middle, the BER pathway initiated by a bifunctional glycosylase with β 
lyase activity is depicted. The glycosylase reaction results in a 3'ddR5P end, which is 
processed by APE1. On the right, a NEIL family glycosylase upon removal of base lesion 
with β/δ lyase activity creates a 1nt-gap with 3'P and 5'P ends; the 3’P is removed by 
PNK. Resulting 1nt-gap is filled by Pol β and the nick sealed by XRCC1/DNA ligase III. 
(B) The LP-BER pathways are shown: the strand-displacement synthesis on the left and 
the hit-and-run model on the right. For more details see text. (From Matthias Bosshard, 
Enni Markkanen, and Barbara van Loon. (2012) Base excision repair in physiology and 
pathology of the nervous system. International Journal of Molecular Sciences) 
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27-30. After Pol β mediated DNA synthesis, X-ray repair cross-complementing 1 protein 
(XRCC1)/DNA ligase III complex seals the resulting nick and completes SP-BER (Figure 4A). 
If the 5’ terminus of the 1nt-gap cannot be processed by Pol β dRP lyase activity, LP-BER sub-
pathway will take place (Figure 4B). This sub-pathway can occur through strand 
displacement synthesis or via the hit-and-run mechanism. It has been suggested that strand 
displacement synthesis is mediated by Pol β, which inserts the first nt, followed by strand a 
invasion step catalyzed by Pol δ or ε. The generated 5’flap is removed by flap endonuclease 1 
(FEN1). The hit-and-run mechanism occurs through alternating insertion of 1nt by Pol β and 
flap removal by FEN1. Independently of the mechanism, LP-BER is completed through 
ligation of the sugar backbone by DNA ligase I 31. Various additional proteins have been 
associated with LP-BER, such as replication factor C (RF-C), proliferating cell nuclear antigen 
(PCNA) and replication protein A (RP-A). 
Previous work showed that BER still takes place even when Pol β was knocked-down 32,33. 
Since Pols β and λ share many structural similarities and belong to the same Pol family, 
investigations into the relevance of Pol λ in this repair pathway have been made. It was 
indeed shown that Pol λ participates in BER 34.  
2.1.1.2 BER of 8-oxo-G 
 
Three different enzymes are associated with the 8-oxo-G metabolism (Figure 5). The 8-oxo-G 
damage, created by oxidation of guanine (G) paired with cytosine (C), is recognized and 
removed by the bifunctional 8-oxo-guanine glycosylase 1 (OGG1) 35. The native G:C base pair 
is restored by subsequent SP-BER. If 8-oxo-G becomes a substrate for replicative Pols before 
OGG1 repair takes place, dATP will be misincorporated opposite 8-oxo-G. The A:8-oxo-G 
mispair is recognized by the monofunctional MutY homolog (MutYH) DNA glycosylase 36, 
which cuts out the adenosine (A) to prevent generation of G:C→T:A transversion mutations 
  
Figure 5. The major protective mechanisms against the oxidative DNA lesion 8-oxo-G. 
Prevention, involving MTH1-catalyzed hydrolysis of 8-oxo-dGTP, to prevent its 
incorporation into DNA by Pols during DNA synthesis. Repair, involving OGG1-initiated 
BER, to repair the C:8-oxo-G base pair to the original C:G base pair. Proofreading operates 
on the A:8-oxo-G mispair. When A is in the newly synthesized DNA strand, it is 
eliminated by MutYH DNA glycosylase, thereby enabling the formation of a C:8-oxo-G 
base pair that can be repaired by OGG1-initiated BER. When A is in the template strand, 
the newly incorporated 8-oxo-G might be removed through mismatch repair (MMR). 
(From Tamar Paz-Elizur, Ziv Sevilya, Yael Leitner-Dagan, Dalia Elinger, Laila C. Roisman, 
Zvi Livneh. (2008). Cancer Letters) 
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in the next round of DNA replication 37. After MutYH and APE1 generated a 1nt-gap, Pol λ 
with the associated dRP lyase activity removes the 5'dRp moiety and, in the presence of co-
factors PCNA and RP-A, places a correct dCTP opposite 8-oxo-G with extension of an 
additional 1nt 38,39. FEN1 and DNA ligase I finalize the repair pathway 39. It was indeed 
shown that while the repair of C:8-oxo-G by OGG1 is generally followed by SP-BER, the 
MutYH initiated repair of A:8-oxo-G mispairs is mediated by LP-BER pathway 21,31. Further, 
exposure of cells to oxidative stress, results in increases levels of MutYH and Pol λ and their 
gathering at the site of DNA damage 39. 
Besides in the DNA, oxidation can also lead to damages in the nucleotide pool and generate 
8-oxo-dGTP. If 8-oxo-dGTP becomes a substrate of Pol, it will be incorporated in the DNA 
opposite an A, since 8-oxo-G in syn conformation mimics T. The human MutT homolog 
(MTH1) is an 8-oxo-dGTPase that hydrolyzes 8-oxo-dGTP so that this damaged nucleotide 
cannot be incorporated into the DNA. If preserved, the misincorporation of 8-oxo-dGTP 
would misguide MutYH to remove the assumed mispaired A from the parental strand and 
thereby produce T:A→G:C transversion mutations 40. 
The OGG1 and MutYH repair machineries scan the DNA explicitly for 8-oxo-G lesions and 
do so against a high background of undamaged bases. Oxidative stress leads to higher levels 
of repair proteins to combat the damage. Alterations in levels of BER components could also 
be targeted to increase sensitivity of cancer cells for therapy 41. Indeed changes in the three 
proteins involved to combat 8-oxo-G damage were associated with diseases such as cancer, 
neurodegeneration or premature aging. One such example is a recent study showing 
increased levels of 8-oxo-G in thyroid adenoma and carcinoma, together with a decrease in 
gene expression of BER proteins in carcinoma and an increase in adenoma 42.  
2.1.2 DNA glycosylases 
2.1.2.1 DNA glycosylases through families 
 
DNA glycosylases remove faulty bases by cleaving the N-glycosylic bond between the base 
and the sugar, thereby creating an AP-site 43. They are specific for different base lesions and 
show either monofunctional or bifunctional activity, as mentioned above. DNA glycosylases 
can be further grouped into four superfamilies with distinguishing structural characteristics 
(Table 2): uracil DNA glycosylases (UDGs), helix-hairpin-helix (HhH) glycosylases, 3-methyl-
purine glycosylase (MPG, also known as AAG) and NEIL glycosylases 22. All of them exert 
their repair function by a flip out mechanism through which the specific base is isolated from 
the DNA helix and placed into a selective active site pocket 44. The different glycosylases then 
use either an internal Lys or Pro as the active site nucleophile for the removal of the 
corresponding base 25. Even though structurally different, many glycosylases have 
overlapping substrate specificity and therefore complement an efficiently connected BER 
system 45,46. 
The glycosylases that engage in oxidative DNA damage are endonuclease III-like protein 1 
(NTH1), NEIL1, OGG1, MutYH and single-stranded selective monofunctional uracil DNA 
glycosylase 1 (SMUG1) 40. With respect to 8-oxo-G lesions, OGG1, MutYH and NEIL1 are the 
most relevant. Nonetheless, all the named glycosylases act together and maximize repair 
efficiency in the cell 47. Deficiencies in DNA glycosylases lead to the accumulation of base 
alterations and finally manifest in the development of diseases 48. Gene expression, 
posttranslational modifications, subcellular localization and recruitment of DNA glycosylases 
to damaged DNA all influence cellular damage recognition and removal capacity 49. 
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2.1.2.2 MutY glycosylase homolog 
MutYH is the human homolog to the E. coli MutY glycosylase. In humans, it is encoded on 
chromosome 1 50. Numerous different isoforms have been identified so far: some of which are 
directed to the mitochondria via an N-terminal domain and others that localize in the nucleus 
through their C-terminal nuclear localization sequence 51,52. Isoform 2 consists of 535 amino 
acids (Figure 6). MutYH carries the characteristic HhH motif important for the recognition of 
A:8-oxo-G mispairs as well as subsequent removal of the undamaged A. Besides A:8-oxo-G, 
human MutYH recognizes other mispairs such as A:G or 2-OH-A:G and reliably removes the 
A or 2-OH-A respectively 53 (Table 2). MutYH from other species shows additional substrate 
specificities. Besides the HhH motif, the iron-sulphur cluster (4Fe-4S) in the catalytic core 
supports binding and repairing of the DNA 54. An unique carboxy-terminal domain and a 
pseudo-HhH moderate substrate specificity by recognizing 8-oxo-G 50,55,56. Highly-structured 
domains are also important for binding to APE1, RP-A and PCNA. As MutYH exerts its 
activity on newly replicated DNA, association with those proteins at the DNA increases the 
glycosylase's affinity and activity for A:8-oxo-G mispairs 57,58. Besides the interaction with 
other proteins, posttranlational modifications influence MutYH activity. Phosphorylation of 
MutYH for example increases its cleavage activity 59. Further, MutYH levels increase during 
S-phase and mitosis, which at least partially correlates with its established role in A:8-oxo-G 
repair 60.  
Table 2. Mammalian DNA glycosylases, their substrates, modes of action, and mutant 
phenotypes. 
(From Angelika L. Jakobs, Primo Schär. (2012) DNA glycosylases: in DNA repair and 
beyond. Chromosoma) 
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Impairment of MutYH function has been associated with several diseases. Even though the 
alterations in activity are often quite modest, sensitivity to oxidative stress is increased in a 
way that genetic mutations accumulate and finally result in pathological changes 61. Certain 
MutYH variants exhibit hampered binding and cleavage activity, while other have decreased 
stability compared to wild-type (WT) protein, resulting in reduced protein levels 62. The most 
widespread and well-studied disease associated with MutYH deficiency is MutYH-associated 
adeomatous polyposis (MAP), a pre-stage of colorectal cancer 63. Germ-line mutations cause 
variant proteins to evolve, which may account for a variety of hereditary cancers 64. In MAP, 
it is often the adenomatous polyposis coli (APC) tumor suppressor gene, which is mutated 
secondarily because of insufficient MutYH activity 65,66. This is in contrast to familial 
adenomatous polyposis (FAP), where the APC gene is primarily mutated 67. Genetic and 
environmental factors as well as tissue-specific expression, alternative DNA repair pathways, 
inflammatory response and the immune system influence the development of cancer 68,69. This 
is also true for MAP, where phenotype, cancer risk and survival vary according to the genetic 
background and extent of inflicted oxidative DNA damage 70,71. Besides the colon, researchers 
suspect cancers of other organs to be associated with MutYH polymorphisms. This applies to 
gastric 72 and endometrial 73 cancers while others such as childhood acute lymphoblastic 
leukemia 74 or squamous oral carcinoma 75 showed no correlation. Former studies propose 
that MutYH also induces apoptosis when oxidative damage exceeds a certain threshold 76. 
Knock-down of both MutYH and OGG1 leads to the accumulation of 8-oxo-G 77 and 
predisposition to lung and ovarian tumors as well as lymphomas 78.  
Overall, it is elevated oxidative stress in certain tissues that pushes cells with deficient 
MutYH towards cancer or, supposedly, neurodegeneration. Fast replicating tissues, as the 
intestines, are characterized with high oxygen consumption due to their active metabolism. 
Similarly, neuronal metabolism is very active with enhanced oxygen usage 79. Tissues 
requiring large amounts of oxygen are in particular sensitive to MutYH status. Therefore, it is 
possible to reason that MutYH also participates in repair of nuclear and mitochondrial DNA 
in the brain, where specific isoforms of the protein exist 80. While MutYH largely appears 
together with PCNA during brain development and neurogenesis, some isoforms dominate 
later during development 77,81. This suggests that MutYH mediates nuclear DNA damage 
repair in replicating neurons and is later on shifted to mitochondria in adult permanent brain 
cells 81. Mitochondria are abundant in neurons (in the cell body as well as in synapses 82) 
because of their high metabolism that asks for an efficient system to repair oxidatively 
damaged DNA 83.  
  
Figure 6. Functional domains of MutYH.  
(From Carla Kairupan, Rodney J. Scott. (2007) Base excision repair and the role of MutYH. 
Hereditary Cancer in Clinical Practice) 
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Deficiencies in the MutYH mediated DNA repair pathway could have severe consequences 
on brain homeostasis. Hypoxia drastically increases oxidative damage and accordingly, it 
was shown that MutYH levels rise after stroke 84. In case of mitochondrial dysfunctions in 
Parkinson's disease, elevations in the levels of MTH1, OGG1 and MutYH were detected 85,86. 
As increased oxidative stress is thought to be one of the main issues in Parkinson's disease 87, 
the repair proteins cannot deal with the total amount of DNA damage, leading to neuronal 
death 88. The importance of functional MutYH initiated DNA repair in the nervous system is 
also demonstrated through altered MutYH levels observed in retinal degeneration of rodents 
or Equine Cerebellar Abiotrophy in Arabian horses. The former is attributed to an age-
dependent decrease of MutYH expression among other repair proteins 89, while the latter 
correlates with a single-nucleotide polymorphism in the MutYH gene 90. Together these 
findings clearly demonstrate the crucial role of MutYH in the maintenance of normal brain 
function. 
2.1.3 DNA polymerases 
2.1.3.1 Eukaryotic DNA polymerase families 
A set of Pols synthesizes DNA during cellular processes such as replication, repair, 
recombination, translesion synthesis and immunoglobulin recombination. The eukaryotic 
Pols are grouped into four families. The members of family A (γ, ν, θ) and B (α, δ, ε, ζ) are 
mainly involved in replication and translesion synthesis (TLS); replicative Pols are 
underlined. Some of them have a 3'→5' exonuclease proofreading activity. Family Y Pols (η, ι, 
κ, Rev1) can bypass various lesions that would otherwise lead to replication fork stalling. The 
Pols of family X (β, λ, µ, TdT) are engaged in different DNA repair steps 91. 
The overall architecture of Pols is conserved in all species and kingdoms from prokaryotes to 
eukaryotes. The catalytic core resembles a right hand with palm, finger and thumb domains. 
The palm carries the catalytic activity with the phosphoryl transfer function. It attaches a 
dNMP to the 3’OH group of the DNA primer and discharges a pyrophosphate. The fingers 
associate with incoming nucleotides and singe-stranded DNA while the thumb binds to the 
double-stranded (ds) DNA. Fingers and thumb are not conserved to the same extent as the 
palm and, besides other differences, account for the specific functions of Pols. 
Defects in Pols relate to a wide spectrum of diseases, for example cancer and hypersensitivity 
to oxidative DNA damaging agents 92. This not only holds true for mutations impairing Pol 
activity, but also for augmented levels or hyperactivity of these proteins. For instance, Y- and 
X-family Pols are regarded as error-prone when compared to replicative Pols. If their activity 
is increased, they work to a higher extent on the DNA and thus can induce mutations. This 
feature of cancer cells is called mutator phenotype. More serious outcome arises when DNA 
replication stress occurs, resulting among others in DNA ds breaks (DSBs) and chromosome 
instability 93,94. Alterations in Pols can therefore not only contribute to cancer by induction of 
mutations, but also affect propagation of clones in cancer development. At the same time, 
response to chemotherapy or radiation as treatment options can be decreased if cancer cells 
have up-regulated TLS Pols 94. After treatment, instead of damaging the DNA to a point 
where the cell enters apoptosis, Pols efficiently bypass harmful lesions and survival is 
possible 93,95. The study of Pols and their properties is an interesting and continuously 
evolving field that enables gain of insights into the molecular processes during pathogenesis 
as well as possible treatment protocols. 
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2.1.3.2 Structure of DNA polymerase λ 
The X-family Pols are involved in BER where they fill small DNA gaps. Pol λ is the most 
widespread X-family Pol among different species and thus is potentially the ancestor of all X-
family members 96. Pols λ and β share approximately 32% homology 97. In humans, Pol λ is 
encoded on chromosome 10 98 and has a predicted size of 63kDa. Highest Pol λ expression 
levels are detected in highly proliferative germline tissues, especially in testis. It is therefore 
suggested that Pol λ potentially plays a role in meiosis. In addition, it is also transcribed in the 
brain, which indicates a role not only in germline but also in somatic cells 99,100.  
Pol λ (Figure 7) contains two non-enzymatic domains at its N-terminus: the breast cancer 
susceptibility gene 1 C-terminal (BRCT) domain and a proline-rich domain. These two 
domains account for the preference to fill the short DNA gaps, in which efficiency and 
fidelity of Pol λ are the highest. While the BRCT-domain mediates protein-protein and 
protein-DNA interactions 101, the proline-rich domain increases the fidelity of Pol λ up to a 
100-fold 102. In general, Pol λ works better on damaged than on undamaged DNA and does so, 
in the case of 8-oxo-G damage, with a higher fidelity than Pol β 103. It is also up to 20-fold 
more efficient on AP sites, with a greater affinity for dNTPs, than Pol β 104. 
 
 
Figure 7. Structure of human DNA polymerase λ core.  
8kDa domain (green), endowed with a dRPase activity and providing additional DNA 
binding capacity; fingers, providing contacts to handle the DNA primer strand through its 
Helix-hairpin-Helix motif; palm, constituting an appropriate surface to accommodate the 
substrate molecules (nucleotides and DNA) and to present the pair of metal ions 
adequately for catalysis; thumb, providing template selectivity and reaction cycling via 
conformational changes. (From Miguel Garcia-Diaz, Orlando Dominguez, Luis A. Lopez-
Fernandez, Lain Teresa de Lera, Maria L. Saniger, Jose F. Ruiz, Maro Parraga, Maria J. 
Garcia-Ortiz, Tomas Kirchhoff, Jesus del Mazo, Antonio Bernad, and Luis Blanco. (2000) 
DNA Polymerase lambda (Pol λ), a Novel Eukaryotic DNA Polymerase with a Potential 
Role in Meiosis. Journal of Molecular Biology) 
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2.1.3.3 Functions of DNA polymerase λ  
Previously, it was shown that Pol λ engages in different DNA repair pathways, from BER, to 
AP site TLS, oxidative DNA damage bypass and non-homologous end joining (NHEJ) of 
DSBs 105-108. For BER, the 8kDa lyase domain is crucial in the step of the AP site processing to 
remove the 5'dRP moiety 97. The HhH motif is another key structure. It allows binding to both 
ends of the gapped DNA, and serves as a stabilizer to assure correct assembly of the free 
DNA ends 109. The processivity of Pol λ is enhanced when the 5'end of the gap carries a 
phosphate group 110. However, as other family X members, it does not possess exonuclease 
activity, cannot proofread and is thus not considered to be highly accurate. Functionally, Pol 
λ forms a complex with MutYH glycosylase at the position of A:8-oxo-G mispair and 
participates in BER 39,111. When MutYH removes the misincorporated A, a correct C has to be 
incorporated. Two auxiliary proteins, PCNA and RP-A, promote repair synthesis mediated 
by Pol λ and at the same time inhibit recruitment of Pol β, a main BER Pol, to the 1nt-gap 
opposite 8-oxo-G (Figure 8). Under these conditions, Pol λ incorporates dCTP 1200-fold better 
than dATP, rendering it the main Pol involved with A:8-oxo-G repair 38,112.  
Even though Pol λ inserts correct nucleotides opposite 8-oxo-G lesions with a high fidelity, it 
has an inclination for frameshift deletions. This happens because the Pol performs strand 
slippage and thereby causes -1 base deletions. Previous studies suggest that the frameshift 
either happens due to misalignment of the active site or when the primer relocates after 
misincorporation of a nucleotide 113-115. Maybe this attribute of Pol λ is connected to its role in 
NHEJ and V(D)J recombination in the production of immunoglobulins 116. When 
summarizing the properties of Pol λ, it is possible to conclude that this Pol is an enzyme 
efficient in short gap-filling synthesis with very little strand displacement, however it is 
prone to frameshift generation.  
Besides direct protein-protein interactions, posttranslational modifications of Pol λ tune its 
activity in the cell. Phosphorylation of Pol λ by Cdk2/cyclin A on Thr553 stabilizes the 
protein and gathers it in the nucleus so that it can act in late S and G2 phases of the cell cycle 
117. As a result, Pol λ accumulates in the period when DNA is replicated and acts on A:8-oxo-
G mipairs generated by replicative Pols. When phosphorylated, Pol λ has a higher affinity for 
MutYH and is more efficiently recruited to the chromatin 118. Interestingly, the polymerase 
activity is not affected by phosphorylation 119. On the other side, Pol λ tightly associates with 
PCNA during S phase when it is hypophosphorylated 119. This interaction enhances the 
assembly and activation of the necessary proteins at the DNA damage sites 38,117,119,120. Levels 
of Pol λ not only increase after replication but also when cells are challenged by ROS 121. 
Indeed it was shown that when phosphorylated, Pol λ is protected from ubiquitination and 
subsequent degradation 119. The main E3 ubiquitin ligase responsible for ubiquitinating Pol λ 
is Mule (for more details see subchapter 2.2.3.). Taken together these findings highlight the 
involvement of Pol λ in the repair of A:8-oxo-G mispairs.  
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2.2 Regulation of BER through ubiquitination 
2.2.1 Ubiquitination 
Ubiquitination is a type of posttranslational modification that plays an important role in 
proteasomal degradation as well as non-proteolytic regulation. Four classes of enzymes 
belong to the ubiquitination machinery: activating E1, conjugating E2, ligating E3 and 
accessory E4 enzymes. They all participate in the attachment of ubiquitin to target proteins 
(Figure 9) 122. Ubiquitin (Ub) itself is a protein that consists of 76 amino acids. Ubiquitination 
is a sequential process that starts by activation of free Ub and its linkage by C-terminus to E1 
through a thio-ester bond in an ATP dependent manner. Ub is subsequently handed over to 
an E2 protein, which then associates with an E3 ubiquitin ligase. In the final step, Ub is 
 Figure 8. Model for the MutYH initiated LP-BER of 8-oxo-G, after misincorporation by 
the replication machinery.  
1) DNA replication over an 8-oxo-G by Pol δ. 2) recognition of an A:8-oxo-G mispair by 
MutYH, removal of the A and formation of an AP site (designated also as B). 3) recruitment 
of APE1 mediated by MutYH/PCNA and generation of 5’P, 3’OH gapped intermediate. 4) 
protection of the 1nt-gap by RP-A and PCNA mediated recruitment of Pol λ, with accurate 
gap filling (dCTP incorporation). 5) PCNA mediated recruitment of FEN1 and removal of 
1nt-flap. 6) ligation of the nick by recruited DNA ligase I and further faithful OGG1 initiated 
Pol β mediated SP-BER of C:8-oxo-G product. Alternatively an inaccurate loop is initiated: 
(A) Pol λ catalyzes inaccurate gap filling; (B) recruitment of DNA ligase III/XRCC1-
mediated by PCNA and ligation of the nick; (C) recognition of A:8-oxo-G mispair by 
MutYH, removal of A and generation of AP site (designated as B); and (D) recruitment of 
APE1 mediated by MutYH/PCNA, generation of 5’P, 3’OH gapped intermediate. This 
creates an opportunity for Pol λ to catalyze accurate LP-BER. (From Barbara van Loon, 
Ulrich Hübscher. (2009) An 8-oxo-guanine repair pathway coordinated by MUTYH 
glycosylase and DNA polymerase λ. PNAS) 
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transferred onto the target protein. The covalent bond is created between the C-terminal Gly 
of Ub and the ε-amino group of a Lys in the target protein 123. The E3 family of ubiquitin 
ligases has many different members that belong either to the homologous to the E6AP 
carboxyl terminus (HECT), ring between ring fingers (RBR), really interesting new gene 
(RING) or U-box subfamilies 124. The diversity of ubiquitin ligases contributes to the substrate 
specificity 125,126. 
 
Various proteins contain ubiquitin binding domains (UBDs) and specifically recognize certain 
types of Ub chains. The structure of ubiquitin chains, defined by the linkage and distribution 
of Ub units, dictates the selection of binding partners 127. In case of monoubiquitination, Ub is 
solitarily attached to a target protein and thereby mediates change in its activity or 
subcellular localization. Furthermore, there are eight different polyubiquitin chains 
characterized by the type of isopeptide links (Lys48, Lys63, Lys6, Lys11, Lys27, Lys33, Met1). 
Most of them are formed between one of the seven conserved Lys and the C-terminus of Ubs. 
Further, linear polyubiquitin chains exist, consisting of Ubs linked through their N-termini 
(Met1).  
The type of linkage between the Ubs as well as between the Ub chain and the target 
determines the fate of the protein. The polymers can be homotypic or heterotypic, with either 
single or mixed linkage types. Also the length of the chains influence the signal character 128 
and a minimum of four ubiquitins appear to be necessary for proteasomal targeting 129. Most 
known are Lys48- and Lys63-linked polyubiquitin chains, the former directing proteins to 
proteasomal degradation whereas the latter mainly recruits binding partners in cell-signaling 
130. The other polyubiquitin chains are named atypical but their abundance and significance is 
being continuously unraveled 131-133. Ubiquitination is therefore not merely a type of post-
translational modification that marks proteins for degradation, but can influence subcellular 
localization, enzymatic activity and interaction capacity of proteins. It participates in 
pathways of apoptosis, cell proliferation, differentiation, neuronal activity, cellular trafficking 
and signaling, DNA repair and many more 134-138. 
As ubiquitination plays a role in many cellular processes, it is also regulated by a variety of 
other proteins. Deubiquitinating enzymes (DUBs) reverse ubiquitination by hydrolysis 139. Up 
to date, many different DUBs have been discovered, some of which are characterized by high 
specificity. Similarly to E3 ligases, DUBs are tightly regulated by other proteins and the 
picture of the ubiquitin proteasome system (UPS) grows constantly 140. Furthermore, defects 
in the ubiquitination pathway are known to cause cancer, neurodegenerative and metabolic 
disorders 141. 
 
 
Figure 9. The ubiquitination pathway.  
See text for more details. (From Alan M. Weissman. (2001) Themes and variations on 
ubiquitylation. Nature Reviews) 
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2.2.2 Mule - E3 ubiquitin ligase 
Mcl1 ubiquitin ligase E3 (Mule; also known as HUWE1, ARF-BP1, Lasu1, Ureb, HectH9, and 
E3 histone) is a 482 kDa protein encoded on the X-chromosome. It is expressed in most tissues 
and locates to the cytoplasm with the exception of testis and brain, where it is largely found 
in the nucleus 142. Mule belongs to the HECT family of E3 Ub ligases, characterized by the 
common C-terminal HECT domain. The HECT domain was first characterized in human 
papilloma virus (HPV) E6-associated protein (E6-AP) 143,144. If E6-AP is mutated, a 
neurological disorder called Angelman syndrome arises 145,146.  
The N-terminal region of the HECT domain (N-lobe) is required for interaction with E2 
enzymes. The conserved Cys of the C-terminus (C-lobe) binds Ub in thioester complexes, 
transfers it to a substrate protein and participates in elongation of polyubiuitin chains 147,148. 
To complete this action, the flexible hinge loop between N- and C-lobe has to undergo 
conformational changes and bring the catalytic Cys of HECT close to the active site of E2. The 
N-terminus outside the HECT domain accounts for substrate specificity.  
Many tumor suppressors are substrates of E3 Ub ligases and alterations in their protein levels 
through E3 enzymes are linked to cancer 149,150. In line with this observation, Mule was found 
to be overexpressed in lung, breast and colorectal carcinomas 151,152. E3 antagonists could 
consequently serve as targets for therapeutical intervention in specific cancers 153,154. 
Conversely, another group found the anti-apoptotic protein myeloid cell leukemia sequence 1 
(Mcl-1) to be ubiquitinated by Mule and degraded thereafter 155. This seems to be a 
contradiction as Mule cannot be an anti-apoptotic mediator in case of p53-ubiquitination and 
at the same time promote apoptosis when ubiquitinating Mcl-1. However, the processes are 
never absolute and maintaining a balance under unstressed conditions is vital, as revealed by 
the regulatory network around Mule (Figure 10). Its activity is directly influenced by the 
alternate reading frame (ARF) protein. ARF is induced in the nucleus after DNA damage, 
binds Mule and thereby stabilizes p53 to arrest cell cycle. Little ARF is present in the 
cytoplasm so that degradation of Mcl-1 by Mule leads to apoptosis 156. This demonstrates that 
Mule is involved in complex pathways to regulate DNA damage and changes in the protein 
may have intertwined effects. 
2.2.3 Mule in BER 
Mule interacts with many proteins and participates in the regulation of cell proliferation, 
apoptosis, DNA damage response and BER 151,155,157. It has recently been shown that Mule 
monoubiquitinates Pol β, which is further polyubiquitinated by the E3 ubiquitin ligase 
carboxyl terminus of Hsc70-interacting protein (CHIP) and sent for proteasomal degradation 
(Figure 10) 158. However, when base lesions are introduced in DNA, Pol β needs to 
accumulate and be active in BER. This is where the ARF protein plays an important role. ARF 
is a tumor suppressor that, upon occurrence of DNA damage, stabilizes p53 and 
consequently leads to induction of cell cycle arrest or apoptosis 159. Mule on the other side 
leads to the proteasomal degradation of p53 160, which is why ARF closes the regulation circle 
by inhibiting Mule upon DNA damage 150,154,161. By doing so, ARF guarantees that p53 and Pol 
β are stabilized to intervene in cell cycle and enable DNA damage repair, respectively. 
Similarly to Pol β, another BER protein, Pol λ, is ubiquitinated by Mule and degraded 
thereafter 121. The consequence of Pol λ ubiquitination and degradation is a reduction in 
correct TLS of 8-oxo-G damage 111,119. 
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Besides targeting other proteins, Mule has the ability to self-ubiquitinate and thus initiate its 
own degradation 150. The extent of Mule ubiquitination is under direct control of 
deubiquitinating enzyme ubiquitin-specific protease 7S (USP7S, also known as HAUSP). It 
has recently been shown that USP7S deubiquitinates Mule and thereby allows the E3 
ubiquitin ligase to keep the levels of p53 low in unstressed cells 162. Without this system, p53 
would accumulate in intact cells and cause delayed proliferation as well as apoptosis 163. 
Besides tumor suppressors and DNA repair proteins, USP7 regulates the activity of other 
substrates important for the immune system, virus replication and epigenetic control 164 
(Figure 11). 
 
Figure 11. USP7 interacts with multiple substrates. 
USP7 substrates are grouped into various functional groups. (Modified after Benjamin 
Nicholson, K.G. Suresh Kumar. (2011) The Multifaceted Roles of USP7: New Therapeutic 
Opportunities. Cell Biochemistry and Biophysics) 
 
 
Figure 10. Regulation of BER by Mule and ARF.  
If not required for DNA repair, Pol β is ubiquitinated by Mule and further targeted via 
CHIP mediated polyubiquitylation for subsequent degradation by the proteasome (left side 
of scheme). However, after detection of DNA damage, ARF accumulates and inhibits the 
activity of Mule, thus stabilizing Pol β and λ to enable DNA repair (right side of scheme). In 
parallel, protein phosphatase magnesium dependent 1G (PPM1G) dephosphorylates USP7S, 
which is then downregulated. The repair of DNA damage will result in a decreased release 
of ARF with a concomitant increased activity of Mule that will downregulate Pol β and λ 
levels. A new adjustment cycle will therefore begin on the detection of increased levels of 
DNA damage. (Modified after Svetlana V. Khoronenkova, Grigory L. Dianov. (2011) 
Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. FEBS letters)  
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In summary, upon induction of DNA damage, p53 as well as DNA repair proteins need to be 
activated. The elements of this axis are controlled by common regulatory proteins, which 
modify the stability or activity of the former by changing their phosphorylation or 
ubiquitination status (Figure 12) 165. While accumulation of p53 affects cells through 
overactivation of cell cycle arrest and apoptosis, abundant Mule was found to be 
overexpressed in a number of tumors 151,160. It impedes BER in cancer cells and upregulates 
tranascription by ubiquitinating Myc and thereby enhancing its activity. Mule thus promotes 
the proliferation and accumulation of mutations. The inactivation of USP7S upon DNA 
damage destabilizes Mule and enables the cell to trigger the repair pathways (Figure 12). 
Overall, regulatory chains are very complex and pose many opportunities for therapeutic 
interventions as well as causes of disease 140,166. 
 
2.3 Neurodegeneration  
The nervous system is a highly specialized organ with numerous terminally differentiated 
cells. Due to a low proliferation rate, the regeneration capacity of the nervous system is much 
smaller in comparison to other tissues. For this reason, most of the neurons have to survive as 
long as their organism. Even small changes in neuronal metabolism, architecture or activity 
disturb physiological functions and quickly manifest symptomatically.  
Neurons build a complex system, however they do not constitute a homogenous cell 
population. They are involved in myriads of processes and as such differ considerably in 
morphology and function. As a result, neurons are characterized by individual gene 
expression patterns and consequently react differently upon exposure to stress or damaging 
agents. Diseases with particular symptoms emerge depending on the type of repair 
deficiency, damaging agent and character of the involved neuron. This principle is referred to 
as selective neuronal vulnerability (SNV) and facilitates the understanding of pathogenesis as 
 
Figure 12. Proposed mechanism for the USP7-dependent regulation of Mule and Mdm2 
protein levels after DNA damage. 
In response to DNA damage, ATM is activated and stimulates activity of PPM1G. PPM1G 
dephosphorylates and destabilizes USP7S, which leads to both Mdm2 and Mule self-
ubiquitination and degradation, with the consequent stabilization of p53 and other 
substrates of Mdm2 and Mule. In unstressed cells, the deubiquitination enzyme USP7S is 
stabilized by phosphorylation, and thus stabilizes both Mdm2 and Mule, which results in 
proteasomal degradation of p53 and other substrates. (Modified after Svetlana V. 
Khoronenkova and Grigory L. Dianov. (2012) USP7S-dependent inactivation of Mule 
regulates DNA damage signalling and repair. Nucleic Acids Research) 
 
  19 
well as symptomatology 167. Based on studies over the previous years, it has become apparent 
that neurons, once differentiated, have to suppress cell cycle to survive 168. If they fail to do so, 
the result is not cell division and proliferation but apoptosis 169. Several neurodegenerative 
disorders have been found to correlate with an elevation in the expression of cell cycle 
proteins 170. If neuronal DNA is damaged and reentry into cell cycle takes place, the course of 
disease instead of repair will be promoted 171. The integrity of the source of all biological 
processes, the DNA, therefore has to be closely monitored and damage repaired efficiently. If 
initiation or activity of any repair pathway is defective, genetic lesions may accumulate and 
finally lead to cell death 172,173 and neurodegeneration 174. In proliferating cells, repair 
pathways are more accessible than in postmitotic cells. While for example accurate 
homologous recombination (HR) repairs DNA strand breaks during proliferation, the more 
error-prone NHEJ prevails in mature cells 175. Thus, some diseases arise as the nervous system 
is still developing, while others when it has already matured. This potentially explains why 
many patients with neurodegenerative disorders often do not suffer from cancer, sterility or 
immune dysfunctions; a set of back-up repair pathways is available in cells with an active cell 
cycle.  
2.3.1 Oxidative DNA damage in the nervous system 
The brain is an organ with a very high metabolism and as such consumes 20% of the 
circulating oxygen in the body 176. The neuronal cells synthesize many proteins but also need 
a lot of ATP to maintain intracellular ion homeostasis important for their excitability. The 
blood-brain barrier effectively shields the brain from exogenous damaging agents so that 
endogenous side-products represent the most significant source of damage to neurons 177. 
Roughly 2% of the absorbed oxygen ends as ROS, the majority of which are generated in 
mitochondria 5,178. Unfortunately, ROS in the brain are not neutralized as effectively as in 
other organs, since concentrations of classical antioxidants in the nervous system are much 
lower. This might cause a higher rate of oxidative DNA damage in neuronal tissue 179. Indeed, 
mitochondrial dysfunction is a strong cause of metabolic diseases in general and 
neurodegeneration in particular 180,181. Since the concentration of iron is high in certain brain 
regions, it further contributes to ROS production through the Fenton reaction 182. On the other 
side, ROS are secondary messengers that deliver information and modulate gene expression 
as well as protein activity 183. They play an important role in the maintenance of synaptic 
plasticity, the capacity of synapses to modulate their signaling intensity 184. The impact of 
oxidative stress also differs according to the type and the amount of ROS, making it necessary 
to tightly regulate their production and decomposition. If ROS accumulate, they can lead to 
pathological changes and induce apoptosis in different ways 185-189. Interestingly, many genes 
on the X-chromosome also contribute to synaptic plasticity, which together with oxidaive 
stress holds interesting implications for neurological diseases 190. 
To synthesize anti-oxidant proteins and repair oxidized components, energy in the form of 
ATP is necessary. If ATP levels in neurons are low, for example due to mitochondrial 
dysfunctions or modifications at the promoters of genes encoding proteins for energy 
production, the cells will not be able to compensate for the harmful effects of ROS. 
Consequently, cells will suffer from oxidative stress with damage to DNA, RNA or lipids. 
Previous studies have shown that the DNA repair enzymes are up-regulated in vulnerable 
neurons 191. If the DNA damage response (DDR) is deficient, a variety of neurodegenerative 
diseases arise, such as amyotrophic lateral sclerosis, Alzheimer's disease or Parkinson's 
disease. 
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Besides ROS and ATP imbalances, Ca2+ dysregulation also contributes to degenerative 
diseases. Ca2+ influences numerous cellular processes, such as gene transcription, cell survival, 
neurotransmitter release and excitability, as well as neurite outgrowth and synaptic plasticity. 
If the transport of Ca2+ or its binding are disturbed, mitochondria can be over-stimulated, 
resulting in increased generation of ROS. If the mitochondrial membrane is severely damaged, 
caspase-dependent apoptosis is initiated and the cell dies 192. Glutamate, an excitatory 
neurotransmittor, additionally increases intracellular levels of Ca2+. Its influx through 
glutamate receptor-ion channels is enhanced in aged individuals, as glutamate levels increase. 
Synapses are thereby destroyed through glutamate excitotoxicity. Taken together, all these 
different players contribute to oxidative neurodegeneration and finally engage in a vicious 
circle (Figure 13).  
 
Vulnerable neurons do not always accumulate all types of DNA damages but they are more 
prone to axon, dendrite and synaptic pathologies than resistant neurons. Clinical approaches 
have been developed, trying to reduce oxidative stress by supplementing antioxidants such 
as vitamin E or metal chelators, thus aiming to support the organism in detoxifying ROS and 
thereby prohibit its sequelae such as proteasomal malfunction and misfolding, mitochondrial 
dysfunction, apoptosis and inflammation 193. Finally the goal would be to target specific 
diseased regions of the nervous system and thereby provide optimal treatment for individual 
patients. 
 
 
Figure 13. Molecular and cellular factors that contribute to the selective vulnerability of 
neurons to oxidative stress.  
The colored arrows that link the mechanistic factors in the figure denote direct relationships 
between them. (From Xinkun Wang and Elias K. Michaelis. (2010) Selective neuronal 
vulnerability to oxidative stress in the brain. Frontiers in Aging Neuroscience). OS: oxidative 
stress. 
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2.3.2 Neurodegeneration and BER 
Neurons possess high transcriptional activity as they permanently stimulate cells that 
surround them and are stimulated themselves. This increases the mutagenic potential, as well 
as the effects of DNA damage, since synthesis of corrupted proteins considerably disturbs cell 
function and transcription can even be blocked entirely 194. Flaws of neuronal functions can be 
measured by several different methods: behavioral experiments, microscopy and 
immumohistochemistry as well as long-term potentiation (LTP). The LTP designates the 
quality of synapses to be excited after a series of high-frequency stimulation. In organisms 
with reduced DNA damage repair, those properties often decay in an age-dependent manner 
and end in neurodegenerative diseases 195,196. 
BER proteins are highly expressed in the brain to prevent oxidative stress. They are present in 
the nucleus as well as in the mitochondria as both organelles contain DNA and are under 
constant pressure of ROS. Consistent with this, the brain expresses the BER enzymes relevant 
for 8-oxo-G metabolism and alterations in several of these proteins are associated with 
neurodegenerative diseases 197. Recently, it has been shown that a type of NER, transcription-
coupled repair (TCR), is also involved in the repair of oxidative DNA damage in neurons198. 
This is of particular importance since neurons use their genome mainly for transcription of 
RNA and defects therein will have the greatest impact on the normal function 199  
Table 3. Examples of neurodegenerative diseases associated with deficiencies in DNA 
repair proteins.  
Different defects in DNA repair can lead to a variety of neurodegenerative diseases. 
(Modified after Matthias Bosshard, Enni Markkanen, and Barbara van Loon. (2012) 
International Journal of Molecular Sciences) 
 
Repair pathway Disease Affected 
proteins 
BER and SSBR X-linked intellectual disability 
Alzheimer's disease 
 
 
Parkinson's disease 
 
Huntington's disease 
 
Amyotrophic lateral sclerosis 
Ataxia-oculomotor apraxia-1 
Spinocerebellar ataxia with axonal neuropathy-1 
Mule 
OGG1, XRCC1, 
UNG, APE1, Pol 
β 
OGG1, MutYH, 
APE1 
OGG1, FEN1, 
Pol δ, Pol ε 
OGG1 
APTX 
TPD1 
MMR Huntington's disease HD 
NER Cockaine Syndrome CSA, CSB, XPG 
DSBR Ataxia telangiectasia 
Ataxia telangiectasia-like disorder 
Nijmegen breakage syndrome 
NBS1 
Mitochondrial Alzheimer's disease 
Parkinson's disease  
Amyotrophic lateral sclerosis 
various 
various 
ALS2 
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In aging organisms, the BER proteins often decrease and DNA lesions build up 200. Previous 
findings have also shown changes in certain components of the BER pathway in different 
neurodegenerative diseases (  
) 201. Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Parkinson's 
disease are the most known and represented neuronal disorders that, among many other 
pathological processes, are connected to deficient BER. Besides their role in 
neurodegeneration, the BER enzymes are also important during reperfusion after ischemic 
brain damage. In this time period, cells accumulate ROS and need higher repair efficiency 
accomplished by up-regulated repair proteins 202.  
A very recent study gained new insight into association between neurodegeneration and 
MutYH 203. As mentioned previously, MutYH can cause apoptosis when cells are under 
strong oxidative stress. It does so by exerting its glycosylase function and leaving behind AP 
sites. Due to high amount of damage, they are not further repaired but instead converted into 
harmful single-strand breaks (SSBs). Poly(ADP-ribose) polymerase 1 (PARP1) binds to the 
SSBs and thereby increases poly(ADP-ribose) polymer (PAR) formation 204. This reaction 
depletes nicotinamide adenine dinucleotide (NAD+) and ATP pools, leading to nuclear 
translocation of apoptosis-inducing factor (AIF) 205. Parallel mitochondrial dysfunction 
activates calpains and initiates the release of cytochrom c, the second pathway of apoptosis. 
The caspase cascade is activated and triggers the degradation of the cellular organelles 206. In 
context with PARP toxicity, intracellular Ca2+ levels rise, which is another indication of 
apoptosis and promotes SNV 207-209. 
While MutYH in this pathway prevents cancer by provoking apoptosis in peripheral tissues, 
it can cause neurodegeneration in the central nervous system as the cells cannot be replaced. 
A careful balance of this enzyme is required to ensure adequate repair of A:8-oxo-G mispairs 
but at the same time to prevent SSB after massive oxidative damage and MutYH 
hyperactivation. However, all the networks and regulation mechanisms are not yet fully 
understood and need further investigation. 
2.3.3 X-linked intellectual disability (XLID) 
Intellectual disability (ID) describes a lack of cognitive abilities, low level of intelligence and 
missing adaptive behavior appropriate for the corresponding age group 210. It affects 2 to 3% 
of the Western population with a male overrepresentation of 30% 211. Patients display limited 
intellectual functions with lacking conceptual, social and practical skills 212. Besides genetic 
causes, prenatal factors such as malnutrition or teratogenic substances can lead to ID. Also 
perinatal complications and postnatal events such as infections or injuries can damage the 
brain 213. Mild cases of ID have an intelligence quotient (IQ) between 50 and 70, while severe 
forms score below an IQ of 50 214. 
XLID, formerly known as X-linked mental retardation (XLMR), is a form of ID originating 
from mutations on the X-chromosome. Because males only have one X-chromosome, they are 
predominantly affected, with an approximate prevalence of 0.1% in the total population 215. 
Other factors that affect the disposition for XLID are differences in the expression of X-genes 
in the brains of males and females or variable protein amounts due to genes that evade X-
inactivation 216.  
About 40% of the 885 proteins encoded on the X-chromosome are expressed in the brain, and 
over 150 of those are predicted to be involved in different forms of XLID. In general, many 
intelligence genes lie on the X and it is therefore disproportionally represented in causes for 
ID 217-219. So far, mutations in 82 X-genes have been identified 220. They encode signaling 
pathways, transcription factors, arrange cytoskeletal organization, cell adhesion and 
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migration as well as maintenance of the cell membrane potential (Figure 14) 221. This makes 
XLID a very heterogeneous disease. Although clinicians distinguish between non-syndromic 
(mental disabilities alone) and syndromic (additional disabilities) forms, there is no 
correlation to the genetic background. Mutations of different genes can evoke similar 
symptoms. At the same time, different conditions can trace back to the same gene. Diagnosis 
and identification of candidate genes is hence a very laborious process. 
 
Examples of distinct XLID forms are the Fragile X mental-retardation syndrome with a 
cloning of the fragile X-linked mental retardation type 1 (FMR1) gene or the Rett syndrome 
with a mutation of the methyl-CpG-binding protein 2 (MECP2) 222. Overall, non-syndromic 
XLID is the most frequent form 217. As mentioned above, many of the proteins altered in XLID 
are involved in neurogenesis and neuronal functions. A change in their amount or structure 
leads to the malfunctions responsible for the final symptoms: imperfect dendrite 
development 223, neurite outgrowth 224, deformed actin cytoskeleton, or synaptic transmission 
and detection problems 225,226. 
Neurons generally do not regenerate and they disappear without replacement after apoptosis. 
To fully grasp the mechanisms of neurodegeneration and subsequent ID, one has to go down 
to the single cellular processes and study all the players involved. Furthermore, identification 
of genes causing XLID also leads to a more profound understanding of the complexities in 
brain development and cognitive function. With new insights, even treatment options may 
arise 227, a very promising and exciting outlook for neuropathologic diseases. 
 
 
Figure 14. Molecular functions of proteins encoded by 82 known XLID genes, according 
to the available Gene Ontology annotations (www.geneontology.org).  
(Modified after Pietro Chiurazzi, Charles E Schwartz, Jozef Gecz, and Giovanni Neri. 
(2008) XLMR genes: an update. European Journal of Human Genetics) 
 
  24 
2.3.3.1 XLID and Mule 
Ubiquitination with its various chain linkage types and effector mechanisms is involved in a 
range of neuronal functions such as synaptogenesis and signal transduction 228. The 
development of the brain is a very complex and highly specialized process where each step is 
crucial for a correct outcome. Also Mule plays important roles in neurogenesis and is 
expressed in the brain among other tissues 160. Knock-down of Mule in mice leads to neonatal 
lethality with severely disturbed brain architecture and differentiation. In malignant brain 
tumors, Mule can be inactivated and thereby disturb the homeostasis in the neuronal tissue 
229,230. Moreover, dysfunction of the UPS is observed in a number of neurodegenerative 
diseases. It has been proposed that polyubiquitin chains accumulate and disrupt cell 
homeostasis in neurons, for example by forming insoluble deposits 231,232. Alzheimer's, 
Parkinson's and Huntington's diseases only represent some the most popular 
neurodegenerative diseases increasingly linked to the UPS 233-236. 
Froyen et al. identified changes in the E3 Ub ligase Mule to be associated with XLID. The 
Mule gene exhibits either point mutations or copy number gains 1,237. Because Mule 
participates in many regulatory pathways in the cell, its alteration can have many and 
potentially intertwined consequences. The main focus of this work is the investigation of the 
impact of Mule on BER by ubiquitination and proteasomal degradation of Pol λ and possibly 
MutYH.  
2.4 Aim of the thesis 
The aim of this thesis was to explore the influences of mutated Mule, identified in patients 
suffering from XLID, on the repair capacity of oxidative DNA lesions. The focus lays upon 
determining: 
 
(i) the status of Mule and proteins important to counteract A:8-oxo-G mispairs,  
(ii) the subcellular localization of the corresponding repair proteins,  
(iii) the ability to efficiently remove A from A:8-oxo-G mispairs, 
(iv) the overall cellular capacity to accurately bypass 8-oxo-G damage, and 
(v) the possibility to rescue the observed effects upon modulating Mule levels. 
  
  25 
3 Material and Methods 
3.1 Common buffers and solutions 
 
G
EN
ER
AL
 
Phosphate 
buffered saline 
(PBS) 1x 
137mM NaCl 
2.7mM KCl 
10mM Na2HPO4 
1.76mM KH2PO4 
pH 7.4 (adjusted 
with HCl) 
 
PBS-T 0.05% 
137mM NaCl 
2.7mM KCl 
10mM Na2HPO4 
1.76mM KH2PO4 
pH 7.4 (adjusted with HCl) 
0.05% (v/v) Tween 20 
 
Tris/Borate/EDTA (TBE) 1x 
90mM Tris 
90mM Boric acid  
2mM EDTA pH 8.0 
 
EDTA pH 8.0 
0.5M EDTA*H2O 
pH adjusted with 
NaOH 
 
EGTA pH 8.0 
0.5M EDTA*H2O 
pH adjusted with NaOH 
HEPES pH 7.9 
1M Hepes* H2O 
pH adjusted with KOH 
DTT 1M 
5g DTT 
32.1ml H2O 
326µl 1M Na-
Acetat pH 5.2 
(adjusted with 
HCl) 
 
WCE buffer A 
10mM Tris-HCl pH 7.5 
1mM EDTA  
1mM DTT 
0.1mM PMSF 
1.5µM Pepstatin 
3µM Bestatin 
2µM Leupeptin  
 
WCE buffer B 
10mM Tris-HCl pH 7.5 
1mM EDTA  
32% Sucrose 
1.28M NaCl 
1mM DTT 
0.1mM PMSF 
1.5µM Pepstatin 
3µM Bestatin 
2µM Leupeptin 
 
Fractionation 
buffer A 
10mM Hepes pH 
7.9 
100mM KCl 
1.5mM MgCl2 
340mM Sucrose 
10% Glycerol 
0.1% Triton 100X 
1mM DTT 
1mM PMSF 
1.5µM Pepstatin 
3µM Bestatin 
2µM Leupeptin 
 
Fractionation buffer B 
3mM EDTA pH 8.0 
0.2mM EGTA pH8.0 
1mM DTT 
1mM PMSF 
1.5µM Pepstatin 
3µM Bestatin 
2µM Leupeptin 
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SD
S-
PA
G
E 
AN
D
 IM
M
UN
O
BL
O
T 
SDS loading 
buffer (Laemmli) 
10x 
600mM Tris-HCl 
pH 6.8 
20% SDS 
20% Glycerol 
0.05% Bromphenol 
blue 
20% β-­‐
mercaptoethanol	  
	  
Odyssey blocking 
solution 
Odyssey blocking 
buffer (Li-Cor) 1:2 in 
PBS-T0.05% 
 
 
TG-gel preparation 
mix 
- lower buffer (4xB) 
1.5M Tris-HCl pH 
8.8 
0.4% SDS 
 
TG-gel preparation 
mix 
- upper buffer (4xC) 
0.5M Tris-HCl pH 6.8 
0.4% SDS 
Bromphenol blue 
 
TG-running buffer 5x 
125mM Tris 
0.96M Glycine 
0.5% SDS 
 
 
TG-transfer buffer 
10x 
250mM Tris 
2M Glycine 
 
TG-transfer buffer 1x 
100ml trans. buffer 10x 
200ml methanol 
700ml H2O 
 
 
TA-gel solution 4x 
1.5M Tris-Acetate 
pH 8.1 
 
TA-running buffer 
20x 
1M Tricine 
1M Tris 
2% SDS 
 
TA-transfer buffer 1x 
25mM Tris 
192mM Glycine 
0.1% SDS 
10% Methanol 
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SE
Q
UE
N
CI
N
G
 G
EL
S 
PA-gel solution 
20% 
20% Acrylamide 
19:1 
0.5% TBE 
 
Annealing buffer 5x 
100mM Tris-HCl pH 7.5 
750mM NaCl 
 
DNA loading buffer 50x 
(PA-gel) 
20% Glycerol 
bromphenol blue 
xylene cyanol blue 
Denaturating 
sequencing gel, 
7M PA-urea, 10% 
420g Urea 
250ml Acryl-bis 
19:1 (40%) 
100ml TBE 10x 
350ml H2O 
Stop buffer 2x (sequencing 
gel) 
96% Formamide 
20mM EDTA pH 8.0 
bromphenol blue 
xylene cyanol blue 
 
PA-urea running buffer 
1x TBE 
 
Gel-fixing 
solution 
850ml (=20%) 
EtOH 96% 
250ml (=5%) 
CH3COOH 
2.9l H2O 
 
  
dN
TP
s &
 O
LI
G
O
s 
dNTPs 
preparation 
stock of 10mM in 
TE pH 7.5 
working prep: 
1mM in TE pH 7.5 
titrations diluted 
in H2O 
 
Oligonucleotide preparation 
stock of 100µM in TE pH 8.0 
working prep: 10µM in TE 
pH 8.0 
labeling concentration of 
2µM in TE 8 
 
 
3.2 Cell-lines and culturing conditions 
3.2.1 Material 
• four lymphoblastoid cell-lines, grown in Roswell Park Memorial Institute (RPMI) 1640 
medium with L-Glutamine, PAA Laboratories GmbH 
• 293T HEK cells, grown in DMEM high glucose (4.5g/l) with stable Glutamine, PAA 
Laboratories GMbH 
• fetal calf serum (FCS) 100%, Gibco 
• penicillin-strepomycin 10'000 U/ml, Gibco 
• DMSO, Sigma-Aldrich 
• Tissue culture testplate 6, TPP 
• Tissue culture flask 25, TPP 
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3.2.2 Lymphoblastoid cell-lines 
a. Patient cells 
One cell-line from the healthy individual (referred to as “wildtype”) and three XLID patient 
lymphoblastoid cell-lines were used in this project. Patient cell-lines, abbreviated as 444, 106, 
and p83, were a gift from G. Froyen (Human Genome Laboratory, Leuven, Belgium) and L. 
Raymond (Cambridge Institute for Medical Research, Cambridge, UK), in whose laboratories 
they had initially been established 1. The cells were isolated from the patients' blood and 
immortalized with Epstein Barr virus as described previously 238. With microarray-
comparative genomic hybridization (array-CGH), quantitative polymerase chain reaction 
(qPCR) and fluorescence in situ hybridization (FISH), the genetic background was 
characterized. The figure below indicates the three XLID-associated mutations in the Mule 
gene (Figure 15). 
Lymphoblastoid cell-line 444 is established from a patient harboring a missense mutation 
R4187C, positioned within the HECT domain of Mule. The patient is only moderately 
intellectually disabled, capable to work and care for himself independently, but sometimes 
has difficulties with articulation and coordination. On the social side, the patient is more 
introverted and rather timid than average. Several members of his family also carry the 
mutation. 
Cell-line 106, derived from a patient displaying severe symptoms of intellectual disability, 
has a Mule mutated at the position 2981, where Arg is replaced by His. This patient 
completely depends on assistance in every day life, lacks speech, has trouble walking as he 
has flexion deformities of the knees and cannot chew properly. The visceral system is also 
affected, as he is not toilet trained. The patient has a younger brother that is affected in a 
similar way. He does not have knee contractures but needs medication for constipation. The 
uncle (mother's side) of the two boys lives in a mental facility because of comparable 
symptoms. 
P83 cells were obtained from a patient carrying a microduplication at the Xp11.22 locus, 
which affects the Mule gene. The patient suffers from severe speech delay, decreased tendon 
reflexes, facial anomalies and social disabilities. His family is affected in a way that several 
members show mental or locomotor pecularities.  
 
 
Figure 15. Mutation sites 444, 106 and p83 duplication in Mule.  
Identification of mutations on the Mule gene in three XLID patients. The mutated base is 
indicated in bold, along with the changed codon for the amino acid. (Modified after 
Svetlana V. Khoronenkova, Grigory L. Dianov. (2011) The emerging role of Mule and ARF 
in the regulation of base excision repair. FEBS letters). Additional data obtained from NCBI 
gene database and Froyen et al. 1  
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b. Culturing 
Cells were grown at 37°C in a 5% CO2 incubator in RPMI medium supplemented with 15% 
fetal calf serum (FCS) and 150 U/ml penicillin-streptomycin.  
For long-term storage, cells were frozen in FCS with 10% DMSO. 
3.2.3 Cell-line HEK 293T  
HEK (human embryonic kidney) 293T cells (American Tissue Culture Collection, USA) were 
grown at 37°C in a 5% CO2 incubator in DMEM medium supplemented with 10% FCS and 
100 U/ml penicillin-streptomycin. 
3.3 CaPO4 transduction of lymphoblastoid cell-lines 
3.3.1 Material 
• HEK 298T cells 
• Lymphoblastoid cells (WT, 444, 106, p83) 
• DMEM medium with 10% FCS and 100 U/ml penicillin-streptomycin 
• RPMI medium with 15% FCS and 100 U/ml penicillin-streptomycin 
• Trypan blue, Sigma-Aldrich 
• Neubauer counting chamber, Hecht-Assistent 
• Plasmid DNA constructs 
– shRNA 1µg/µl: Mule, Scrambled (Open Biosystems) 
– psPAX2 1µg/µl: packing (Open Biosystems) 
– pMD2.G 0.5µg/µl: envelope (Open Biosystems) 
– 2.5M CaCl2 
• Hank's Balanced Salt Solution (HBSS) 2x 
• Tissue culture dishes 60x16mm, TPP 
• Tissue culture testplate 6, TPP 
• syringe-filter 0.45µm, TPP 
• polybrene (hexadimethrine bromide), Sigma-Aldrich 
• puromycin 10µg/ml for selection of transfected lymphoblasts, Gibco 
3.3.2 Method 
Transduction comprises the introduction of foreign DNA into an eukaryotic cell by using a 
viral vector. The DNA is randomly integrated into the host genome, where it is transcribed. 
In our experimental setup, the vector contained information for synthesis of nonspecific 
short-hairpin RNA (shNs) or shRNA targeting endogenous Mule (shMule) transcript. In 
addition to shRNA, constructs encoded green-fluorescent protein (GFP), allowing 
visualization of transduction efficiency and expression level microscopically. 
The virus carrying information for synthesis of shNs and shMule RNA was produced in HEK 
293T cells, according to following protocol. 2*106 HEK 293T cells were plated in a 6cm dish 
24h prior to transfection. The plasmid DNA, prepared as described above, was then pipetted 
dropwise into bubbling HBSS 2x and incubated for 5min at room-temperature (RT) until a 
chalky white precipitate formed. The DNA was added to the corresponding 293T HEK dish 
and mixed by gentle shaking. The cells were incubated for 16h at 37°C in a 5% CO2 incubator, 
after which 5ml DMEM medium was exchanged and the cells incubated for another 24h. The 
virus-containing supernatant was then harvested by filtration through a sterile 0.45µm filter.  
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Of each lymphoblastoid cell-line, 500'000 cells were counted and plated in a 12-well plate 
with a final volume of 1ml. The cells were then infected by adding 1ml of respective virus 
suspension; virus encoding shMule for the knock-down and shNs for the control. To increase 
the infection-efficiency of lymhoblastoid cells, polybrene was added to the virus-containing 
supernatant to reach a final concentration of 4µg/ml.  
The cells were regularly checked for green fluorescence and the medium exchanged on a two-
day basis. After four days, the cells were put under selection with 1µg/ml puromycin. After 
ten days the cells were further propagated by transferring to a 6-well plate, and finally flasks 
six days later. 
3.4 Whole-cell extract preparation from lymphoblastoid cell-lines 
3.4.1 Material 
• PBS 1x 
• WCE buffer A and B 
• Centrifuge 5417R, Eppendorf 
• Rotanta 460 and Rotanta 420R, Hettich 
• Tissue grind pestle SC 2ml, Kontes Gerresheimer 
• Diagenode Bioruptor Standard sonicator (UCD-200 TM) with Digital 1/Neslab RTE7 
Thermo Scientific cooler 
• Bio-rad Protein assay, Dye reagent concentrate, Bio-Rad 
• Genesys 10 UV Scanning, Thermo Scientific 
3.4.2 Harvesting cell pellets  
The cells were grown to confluency in the flasks, resuspended and transferred into a 15ml-
falcon tube. Cells were pelleted by centrifugation 5min, at RT, 250 rcf; supernatant was 
removed and cells washed with 5ml cold PBS. From this point, all subsequent steps were 
performed on ice. Cells were pelleted for a second time, by centrifugation for 10min at 4°C 
and 250 rcf. The supernatant was removed and the pellet resuspended in 1ml cold PBS. The 
cells were then transferred into 1.5ml Eppendorf tubes and spun down one last time for 
10min at 4°C and 250 rcf. Supernatant was removed and the pellet snap-frozen in liquid 
nitrogen. Samples were stored at -80°C until use. 
3.4.3 Whole-cell extract preparation from lymphoblastoid cell-lines 
The protocol for whole-cell extraction was modified after Tanaka et al. 239. Cell-pellets were 
thawed on ice, cells resuspended with 250µl WCE buffer A and let to swell for 20min on ice. 
Cells were disrupted by 20 strokes with pestle B in Dounce Homogenizer. Next, 125µl WCE 
buffer B was added and cells incubated on ice for an additional 5min. They were then 
sonicated twice for 30s with a 30s interval at 4°C and high power. After centrifugation for 
20min at 4°C and 15'000 rcf, supernatant was removed and aliquoted. The samples of WCE 
were snap-frozen with liquid nitrogen and stored at -80°C until further use. 
To determine the protein concentration, the Bradford protein assay was used. The Bradford 
solution contains Coomassie-Brillant-Blue G-250 with phosphoric acid. Upon adding it to a 
sample, it forms complexes with the side chains of the proteins therein, mainly the basic and 
aromatic residues. This reaction changes the absorption, which is photometrically measured 
at 595nm. To receive the calculation curve, first blank was set and four standards (bovine 
serum albumin of known concentration) were measured.  
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3.5 Fractionation of lymphoblastoid cell-lines 
3.5.1 Material 
• PBS 1x 
• Fractionation buffer A and B 
• Rotor mixer 10, Greiner 
• Centrifuge 5417R, Eppendorf 
• Rotanta 460 and Rotanta 420R, Hettich 
• Branson Sonifier Cell disruptor B15, Branson Sonic Power Company 
• Bio-rad Protein assay, Dye reagent concentrate, Bio-Rad 
• Genesys 10 UV Scanning, Thermo Scientific 
3.5.2 Harvesting cell pellets  
Cell pellets were prepared following the procedure described in subchapter 3.4.2. For 
subsequent fractionation experiments, frozen as well as fresh cell pellets were used. 
3.5.3 Fractionation of lymphoblastoid cell-lines 
Protein complexes localized in different cellular compartments can be separated by a 
fractionation procedure that results in cytoplasmic, nuclear and chromatin fractions. To 
fractionate lymphoblastoid cells the previously established protocol by Mendez and Stillman 
240 was optimized. Cells were resuspended with 200µl fractionation buffer A and let to swell 
5min on a rotor at 4°C. Samples were next centrifuged 5min at 4°C and 1700 rcf, yielding 
supernatant 1 and pellet 1. Supernatant 1 was further clarified by centrifugation for 15min at 
4°C and 20'000 rcf; the resulting supernatant represented the cytoplasmic fraction. 
Pellet 1 was respuspended with 200µl fractionation buffer B and let 5min on a rotor at 4°C. 
Centrifugation for 5min at 4°C and 2000 rcf yielded supernatant 2 representing the 
nucleoplasm, and pellet 2. Pellet 2 was resuspended with 200µl fractionation buffer A and 
shortly vortexed. It was then sonicated at 30% intensity with 15 pulses and finally centrifuged 
5min at 4°C and 20'000 rcf. Supernatant 3 represented the soluble chromatin fraction. 
To determine the protein concentration, the Bradford protein assay was applied. To receive 
the calculation curve blank was set and four standards (bovine serum albumin of known 
concentration) were measured. The fractions were subsequently subjected to immunoblot 
analysis. To confirm that each fraction contained expected subcellular components, three 
proteins were utilized as markers: tubulin for the cytoplasm, fibrilarin in case of 
nucleoplasam and histone H1 for the soluble chromatin.  
3.6 SDS-PAGE 
3.6.1 Material 
• MiniSpin centrifuge, Eppendorf 
• SE250 Mighty Small II for 8x7cm gels, Hoefer 
• SDS loading buffer 2x and 10x (Laemmli) 
• PageRuler(TM) prestained protein ladder, Fermentas 
• HiMark prestained protein standard, Invitrogen 
• Immobilon-P transfer membrane, PVDF, Millipore 
• TG- and TA-running buffers 
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• Whattman filter paper, Macherey Nagel 
• Mini Trans-Blot Cell, Bio-Rad 
 
Table 4. Protocol for 10% Tris-Glycine gel 
 
 Stacking  gel (4.8%) 
Separating 
gel (10%) 
H2O 3.15ml 4ml 
lower buffer (4xC) 1.25ml --- 
upper buffer (4xB) --- 2ml 
40% Acryl-bis 37.5:1 0.6ml 2ml 
10% ammonium persulfate 0.05ml 0.08ml 
TEMED 0.005ml 0.008 
 5ml 8ml 
 
Table 5. Protocol for 7% Tris-Acetate gel 
 
H2O 9.2ml 
4x TA-solution 4ml 
40% Acryl-bis 37.5:1 2.8ml 
10% ammonium persulfate 0.16ml 
TEMED 0.016ml 
 16ml 
3.6.2 Method 
To quantify the protein levels in the WCEs and cell fractions of the four lymphoblastoid cell-
lines, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and imunoblot 
analysis were performed. As the proteins of interest have different sizes, ranging from 30 to 
480kD, two different setups were chosen. Proteins of the lower molecular weight were 
separated on 10% Tris-Glycine gels whereas the high molecular weight proteins were 
analyzed on 7% Tris-Acetate gels. The protocols for the gel mixes are provided in subchapter 
3.6.1. 
SDS loading buffer was added to the extracts to reach a final 1x dilution and the samples and 
everything was subsequently heated for 5min at 95°C. Loading buffer, followed by heating, 
causes the proteins to denaturate, charges them negatively and breaks disulfide bonds. After 
heating, samples were shortly spun-down, loaded and run on the gels for 20min at 80V, 
followed by 125V. 
3.7 Immunoblot analysis 
3.7.1 Material 
• TG- and TA-transfer buffers 
• Odyssey blocking solution, Li-cor 
• Primary antibodies: in Odyssey blocking buffer 1:2 in PBS 1x, 0.01% NaN3 
– MutYH (mouse), Abcam (#ab55551), dilution 1:500	  
– Pol λ (rabbit), Bethyl Lab. (#A301-640A-1), dilution 1:1000 
– Lasu1/Ureb1 (Mule, rabbit), Bethyl Lab. (#A300-486A), dilution 1:000 
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– Tubulin (mouse), Sigma-Aldrich (DM1A), dilution 1:10'000 
– Fibrillarin (mouse), abcam (#ab4566), dilution 1:1000 
– Histone H1 (mouse), Santa Cruz (#sc-8030) dilution 1:500 
• Secondary antibodies: in PBS-T 0.05% and 0.01% NaN3 
– IR-680 Mouse IgG, (from goat), Li-cor, dilution 1:15'000 
– IR-800 Rabbit IgG, (from goat), Li-cor, dilution 1:15'000 
• Platform shaker Duomax 1030, Heidolph 
• Odyssey CLx infrared scanner, Li-Cor 
• GelEval, Frog Dance Software 
• Prism, GraphPad Software 
3.7.2 Method 
To obtain a good-quality blot, it is important to avoid any dirt or bubbles between the gel and 
the PVDF membrane. Therefore, the blotting sandwich was assembled in H2O as follows: (i) 
three Whatman filter papers were laid on a wet sponge, (ii) the gel was placed and the 
membrane added on the top, after 1min activation in methanol, everything was covered with 
(iii) another three Whatman filters and a wet sponge. The layers were gently rolled to squeeze 
out any air. 
The transfer occurred in cold either TG- or TA-running buffer, for 1h at RT at 100V, or over-
night at 4°C and 30V. The membrane was blocked for 1h in Odyssey blocking buffer 1:2 in 
PBS-T 0.05%, followed by incubation with the primary antibody of choice for 2h at RT. Before 
adding the secondary antibody for 1h at RT, the membrane was washed three-times for 5min 
in PBS-T 0.05% and finally kept in PBS at 4°C. 
The pictures were obtained on Odyssey CLx infrared scanner, quantified by GelEval software 
and analyzed in Prism. Then, a one-sample two-sided t-test was applied. 
3.8 DNA oligonucleotides 
3.8.1 Material 
Oligonucleotides were purchased from Microsynth. The sequences are shown below: 
OHü 317: 39mer 
5’-TACAACCAAGAGCATACGACGGCCAGTGCCGAATTCACA-3’ 
BvL 38: P-60mer 
5’-GGTGTTGTGTGTTGGTTGTGGTGGTGTTGTGTGGTTGTTGGTGTTGTGTGTGTTGGT 
GTG-3’ 
OHü 318: 100mer (X = 8-oxo-G) 
5’-CACACCAACACACACAACACCAACAACCACACAACACCACCACAACCAACACA 
CAACACCXTGTGAATTCGGCACTGGCCGTCGTATGCTCTTGGTTGTA-3’ 
OHü 322: 100mer 
5’-TACAACCAAGAGCATACGACGGCCAGTGCCGAATTCACAAGGTGTTGTGT 
GTTG GTTGTGGTGGTGTTGTGTGGTTGTTGGTGTTGTGTGTGTTGGTGTG-3’ 
BvL 37: 35mer 
5'-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-3' 
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3.8.2 Method 
The oligonucleotides were used to prepare DNA substrates for polymerase and glycosylase 
assays or as trap-DNA. The stock with final concentration of 100µM was prepared by 
dissolving the oligonucleotides in TE pH 8.0, heating for 10 minutes at 65°C, followed by a 
short spin-down and storage at -80°C. 
3.9 Labeling and annealing of DNA 
3.9.1 Material 
• Oligonucleotides 
– OHü 317: 39mer, upstream primer 
– OHü 318: 100mer, template 
– OHü 322: 100mer 
– BvL 38: P-60mer, downstream primer 
• T4 Polynucleotide Kinase (PNK), Thermo Scientific 
• Buffer A PNK 10x, Thermo Scientific 
• γP32-ATP, 110 TBq/mmol, Hartmann Analytic 
• MicroSpin G-25 column, GE Healthcare 
• Annealing buffer 5x 
• DNA loading buffer 
• 20% PA-gel 
• 0.5x TBE running buffer 
• X-ray film cassette, Okamoto 
• Typox TX-RP blue sensitive film, Raymed Imaging 
3.9.2 DNA labeling 
To radioactively label OHü 317 oligonucleotide for polymerase, or OHü 322 for glycosylase 
assay, the reaction was prepared as depicted in Table 6. 
 
Table 6. Protocol for labeling reaction 
 
H2O 4.5µl 
OHü 317/322 (2µM) 2µl 
Buffer A PNK 10x 1µl 
T4 PNK 0.5µl 
γ32-ATP 2µl 
 10µl 
 
The labeling reaction was incubated for 1h at 37°C in a water bath, after which 19.5µl of H2O 
was added. The labeled DNA was separated from free γP32-ATP by spin-column 
chromatography on a G-25 column, according to manufacturer's instructions. Briefly, the 
labeling reaction was added on the top of pre-equilibrated column, and subjected to 
centrifugation for 2min at 720 rcf. 8µl of annealing buffer 5x was added to purified labeled 
DNA.  
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3.9.3 Annealing 
The 5’ labelled oligonucleotide of interest was annealed to the complementary unlabeled 
DNA. The annealing of oligonucleotides was achieved by addition of 5pmol of 
complementary DNA to the labeling reaction, described in 3.9.2., containing 4pmol of labeled 
primer. The reaction was heated 5min at 95°C, followed by gradual cooling to RT. 
For polymerase assays, a substrate containing 1nt-gap opposite an 8-oxo-G damage was 
generated by annealing radioactively labeled OHü 317 and BvL 38 oligonucleotides to OHü 
318 100-mer. The downstream BvL 38 primer contains a phosphorylated 5'-end so that a 1nt-
gap substrate resembles as close as possible a natural BER intermediate.  
To determine MutYH glycosylase activity, an in vitro glycosylase assay was employed. As 
substrate served double stranded DNA containing the mispaired A opposite an 8-oxo-G 
lesion. The labeled oligonucleotide OHü 322 carries the faulty A, which can be recognized 
and excised by MutYH DNA glycosylase.  
3.9.4 Annealing check 
To test the efficiency of annealing, 20fmol of either (i) labeled or (ii) labeled and annealed 
DNA template was mixed with DNA loading buffer. Samples were loaded on a 20% PA-gel 
and separated by electrophoresis for 1.5h at 300V. The position of annealed and non-annealed 
oligonucleotides on the gel was detected by autoradiography. The non-annealed DNA is 
lighter and thus migrates faster than the annealed DNA. Based on the difference in signal 
height, it is possible to conclude whether annealing was successful or not. 
3.10 DNA glycosylase assay 
3.10.1 Material 
• MutYH reaction buffer 10x  
– 250mM Sodium-phosphate buffer pH 6.8 
– 50mM EDTA  
– 15% Glycerol 
– 500µM ZnCl2 
– 75mM MgCl2 
• Substrate DNA: 100/100-mer containing A mispaired opposite 8-oxo-G  
• recombinant GST-MutYH was purified as described previously 39 
• MutYH dilution buffer 
– 30mM Tris-HCl pH 7.5 
– 1mM EDTA  
– 1mM β-mercaptoethanol 
– 50mM NaCl 
– 30% Glycerol 
• Stop buffer 2x 
• 10% PA-urea gel 
• TBE running buffer 1x 
• X-ray film cassette, Okamoto 
• Typox TX-RP blue sensitive film, Raymed Imaging 
• GelEval, Frog Dance Software 
• Prism, GraphPad Software 
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3.10.2 Method 
No efficient in vitro DNA glycosylase assay has been established so far to determine the 
activity of endogenous MutYH in WCE from cells in which MutYH had not been 
overexpressed. The comparison of endogenous MutYH activity in different lymphoblastoid 
cell-lines thus represented a challenge, with a series of steps needed to establish the optimal 
assay conditions. The development of the MutYH glycosylase assay using WCE is described 
in Figure 18. The optimal reaction conditions are presented in Table 7. To each premix 
reaction, 4µl of WCEs was added with varying final protein concentrations as indicated in 
figure legends. For positive control 0.5pmol recombinant GST-MutYH was used, while as 
negative control served WCE buffer A+B.  
The samples were incubated 5min at 37°C. To break the sugar backbone at the position of AP 
site, 1µl of 2M NaOH was added to each reaction, followed by incubation for 15min at 70°C. 
The reactions were stopped by adding 11µl stop buffer 2x to each tube. The samples were 
heated for 5min at 95°C and shortly spun-down. To distinguish between unrepaired and 
MutYH processed products, samples were loaded on a 10% PA-urea gel and subjected to 
electrophoresis for 2h at 90W in 1x TBE running buffer. The gel was then exposed on film at -
80°C and the positions of DNA oligonucleotides detected on the principle of autoradiography. 
 
Table 7. Protocol for glycosylase reaction premix. All components are listed. 
 
 1r  
H2O 4.55 µl 
MutYH dil. Buffer (10x) 1 µl 
ATP (40mM) 0.25 µl 
Substrate-DNA (100nM) 0.2 µl 
WCE (varying conc.) 4 µl 
 10 µl 
 
3.10.3 Data analysis 
The products of the MutYH glycosylase assay were quantified in GelEval software and 
analyzed in Prism. Then, a one-sample two-sided t-test was applied. 
3.11 DNA polymerase assay 
3.11.1 Material 
• Polymerase buffer 10x 
– 1M Tris-HCl pH 7.5 
– 10mg/ml BSA 
– 1mM DTT 
• Trap-DNA: PolyA 35mer (BvL 37) 
• Aphidicolin from Nigrospora sphaerica, Sigma-Aldrich 
• Substrate-DNA: 1nt-gap opposite 8-oxo-G 
• recombinant Pol λ was purified as described previously 241 
• Pol λ dilution buffer 
– 20mM Tris-HCl pH 7.5 
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– 100M NaCl 
– 1mM DTT 
– 20% Glycerol 
• dNTPs, Sigma-Aldrich 
– dA/G/TTP stock of 1mM, further diluted with H2O 
– dC/G/TTP stock of 2mM, further diluted with H2O 
• Stop buffer 2x 
• 12.5% PA-urea gel 
• TBE running buffer 1x 
• Fixing solution 
• Gel Dryer Model 583, Bio-Rad 
• Storage Phosphor Screen, Molecular Dynamics 
• Typhoon 9400 Variable Mode Imager, GE Healthcare 
• GelEval, Frog Dance Software 
• Prism, GraphPad Software 
3.11.2 Method 
To assess the differences in the activity and fidelity of repair synthesis between different 
lymphoblastoid cell-lines, an in vitro DNA polymerase assay was performed. A reaction 
premix was prepared as depicted in Table 8 and contained following components: (i) 1 mM 
MgCl2 (ii) aphidicolin to inhibit the B-family Pols 242 and (iii) trap-DNA needed to occupy 
DNAses in the WCEs, thus preventing degradation of the substrate-DNA. To each reaction 
5µg of the WCE was added. dNTPs were titrated in the reaction to reach a final concentration 
of 1, 5 and 10µM, respectively. The 0µM dNTP sample contained H2O instead dNTPs. The 
final volume of each reaction was 10µl. A reaction with 5µM dNTPs and WCE buffer A+B 
represented a negative control, while the positive control contained additional 50fmol Pol λ. 
  
Table 8. Protocol for polymerase reaction premix. All components are listed. 
 
 1 reaction  
H2O 1.2 µl 
MgCl2 (100mM) 0.1 µl 
Polymerase buffer (10x) 1 µl 
Trap-DNA (1.36µg/µl) 1.5 µl 
Aphidicolin (10µg/µl) 1 µl 
Substrate-DNA (100nM) 0.2 µl 
dNTPs (0, 1, 5, 10µM) 1 µl 
WCE (1.25µg/µl) 4 µl 
 10 µl 
 
All samples were incubated for 30min at 37°C. The reactions were stopped by addition of 
10µl stop buffer 2x to each reaction. The formamide in the stop buffer denaturates the 
proteins and the EDTA captures the metal-ions so that the catalytic activity of the 
polymerases is additionally inhibited. To denature the DNA, samples were heated for 5min at 
95°C.  
The products of the polymerase assay were separated on a 12.5% PA-urea gel. Samples were 
loaded on the gel and subjected to electrophoresis for 3.5h at 90W in 1x TBE running buffer. 
Upon completion of electrophoresis, the gel was disassembled and fixed for 30min in fixing 
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solution. It was then vacuum-dried for 2h at 80°C and exposed on a phosphoscreen-casette 
over-night. The scan was obtained and visualized by Typhoon imager. 
3.11.3 Data analysis 
The products of the DNA polymerase assay were quantified by GelEval software and 
analyzed in Prism. Then, a one-sample two-sided t-test was applied. 
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4 Results 
4.1 Protein levels of Mule, MutYH and DNA polymerase λ are individually 
changed in XLID patient cell-lines 
As all three XLID patients carry mutations along the Mule gene, an immunoblot analysis was 
first performed to investigate the abundance of the proteins. The duplication of the gene in 
patient p83 leads to an at least two fold increase of Mule. 106 displays a tendency for a slight 
increase while levels are normal or mildly decreased in 444, when compared to healthy 
individual (WT) cell-line (Figure 16A and C).  
 
 
The levels of the three DNA repair proteins in WCEs from XLID patient cell-lines were 
subsequently evaluated by immunoblot analysis. MutYH and Pol λ, the two proteins crucial 
for efficient and accurate repair of A:8-oxo-G mispairs, were found to be changed. This 
finding is in agreement with the previous unpublished data obtained in this laboratory 
(Bosshard M. and van Loon B., unpublished). MutYH levels showed a clear decrease in cell-
line 106 when compared to WT, while 444 cell-line had slightly increased amounts of MutYH 
(Figure 16B and D). Pol λ, was reproducibly reduced by 10% in 444 cell-line (Figure 16B and 
 
 
Figure 16. Changes of Mule, MutYH and DNA polymerase λ levels in three XLID 
patient cell-lines compared to one healthy individual.  
Immunoblot analysis of (A) Mule and (B) MutYH and Pol λ protein levels in WCEs 
obtained from one healthy individual (WT) and three XLID (444, 106 and p83) patient cell-
lines relative to tubulin. The numbers below the bands indicate the change in protein 
amount compared to WT. Quantification of changes in (C) Mule, (D) MutYH and (E) Pol λ  
protein levels from at least three independently performed experiments as the one in (A) 
and (B). Error bars indicate S.D., p-values *≤ 0.05, **≤ 0.01, ***≤ 0.001. 
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E). These findings indicated that the levels of BER proteins MutYH and Pol λ are mis-
regulated in XLID patient cells.   
4.2 Analysis of MutYH and DNA polymerase λ  levels in cytoplasmic, 
nucleoplasmic and soluble chromatin fractions of XLID patient cell-lines 
Besides general protein changes observed by WCE analysis, it is possible that the four 
analyzed cell-lines differ in the subcellular distribution of MutYH and Pol λ, which would 
directly affect their availability to participate in DNA repair processes. To determine 
subcellular distribution of these two proteins in lymphoblastoid cells, fractionation into 
cytoplasm, nucleoplasm and soluble chromatin was performed (Figure 17A). After 
establishing the conditions applicable to lymphoblastoid cells, the fractions were analyzed by 
immunoblot for MutYH and Pol λ levels. Three well established marker proteins served to 
confirm the fractionation efficiency: tubulin for the cytoplasm, fibrillarin in case of 
nucleoplasam and histone H1 for the soluble chromatin (Figure 17B). Though three markers 
are predominately present in the expected fractions, slight carryover is observed. 
Similar to the WCEs (Figure 16), MutYH levels in the cytoplasmic fraction were increased in 
444 but reduced in 106 cell-line. The levels of Pol λ were decreased in 444 cells, as well as 106. 
This pattern was mirrored in the nucleoplasm, however with additional decrease of both 
MutYH and Pol λ in p83 cell-line. In the chromatin fraction, the notable changes are a 
decrease of MutYH in 106 and Pol λ of in all three XLID patient cell-lines.  
 
 
Figure 17. MutYH and DNA polymerase λ levels in cytoplasmic, nucleoplasmic and 
soluble chromatin fractions of WT, 444, 106 and p83 cell-lines.  
(A) Scheme of fractionation principle into cytoplasm, nucleoplasm and soluble chromatin. 
(B) Immunoblot for compartment markers tubulin, fibrillarin and histone 1 indicating 
fractionation efficiency. MutYH and Pol λ protein levels in (C) cytoplasm relative to tubulin, 
(D) nucleoplasm relative to fibrillarin, and (E) soluble chromatin relative to histone 1 in 
fractionation extracts obtained from one healthy individual (WT) and three XLID (444, 106 
and p83) patient cell-lines. The numbers below the bands indicate the change in protein 
amount compared to WT.  
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4.3 Establishment of a MutYH DNA glycosylase assay in whole-cell extracts 
To test whether the reduction in MutYH protein levels observed in the XLID patient cells 
affects overall ability to recognize A:8-oxo-G mispairs and remove the A, an in vitro MutYH 
DNA glycosylase assay was developed. So far no efficient in vitro glycosylase assay had been 
established to determine the activity of endogenous MutYH glycosylase in WCEs. 
 
First whether the concentration of NaCl present in the reaction affects MutYH activity was 
tested, since it was shown that at concentrations higher than 200mM MutYH activity was 
impaired 243,244. Recombinant MutYH was tested under three different NaCl concentrations 
(50, 60 or 160mM) (data not shown). Since MutYH was active under all three tested 
conditions, the protocol for the WCE preparation was chosen so that the final concentration of 
NaCl in the glycosylase assay did not exceed 160mM NaCl.  
Initial time-course experiments using WT and different XLID WCEs revealed that MutYH 
glycosylase activity can be detected in the extracts (Figure 18A). However, a varying degree 
of reduction in the substrate signal could be observed with time in all the WCEs, indicating 
that different extracts contain different amounts of phosphatases (Figure 18A). To divert 
phosphatases from substrate DNA, ATP was added to the reaction (Figure 18B). Though 
addition of ATP resulted in slight suppression of phosphatase activity, the effect was by no 
means sufficient to accurately compare glycosylase activity between the extracts (Figure 18B). 
Besides ATP to attenuate phosphatases, Tris-HCl in the MutYH reaction buffer was 
 
 
Figure 18. MutYH glycosylase can be measured in whole-cell extracts.  
(A) Variation of time from 0 to 180 minutes in the reactions containing WT or XLID (444, 106 
or p84) WCEs. (B) Addition of ATP to glycosylase reactions containing different extracts as 
the one described in (A). (C) Assay using WCEs prepared using sodium phosphate buffer 
and no sonication. (D) Titration of phosphatase inhibitors in the reactions containing WT or 
XLID ( 444, 106 or p84) WCE, with the incubation time of 5 minutes. 
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exchanged with sodium phosphate buffer. Even though the effect of phosphatases still was 
not evenly distributed between the WCEs, an improvement was observed in reactions 
containing sodium phosphate buffer, which was therefore used for further experiments (data 
not shown). 
Since it was shown that presence of free DNA inhibits MutYH activity of substrate DNA 245, 
the WCE were prepared in sodium phosphate buffer, but without the final step involving 
sonication and shredding of genomic DNA (Figure 18C). Even though the loss of substrate 
signal was almost completely abolished, indicating that phosphatases have not been present 
or active in the WCE, the product signal was also almost completely lost (Figure 18C). Thus 
suggesting that sonication is a necessary step in WCE preparation, needed to remove MutYH 
bound to the chromatin. Based on these findings following WCEs were prepared according to 
the initial procedure. 
The next important parameter of the assay was the incubation time. Variation of incubation 
time from 0 to 180 minutes indicated that a longer incubation did not significantly enhance 
the product signal but gave the phosphatases more time to degrade the substrate DNA (data 
not shown). The 5min time point was thus chosen as ideal incubation period allowing 
detection of glycosylase activity and limiting the effect of phosphatases. To understand 
whether addition of phosphatase inhibitors could further improve the quality of the signal, 
the 5min condition was used and phosphatase inhibitors were titrated (Figure 18D). The 
signal reduction was too grave and the improvement of the shorter incubation sufficient so 
that phosphatase inhibitors were left away. Based on these optimization experiments, final 
conditions were established as summarized in Table 9. 
 
Table 9. Conditions to assay MutYH glycosylase in whole-cell extracts.  
Assay optimization resulted in the final reaction conditions depicted in this table. Besides 
listed components, during optimization, reactions contained also 35mer PolydA trap-DNA, 
or the three phosphatase inhibitors (NaF, Na4P2O7, (HOCH2)2CHOP(O)(ONa)2).   
 
NaCl 
(final) 
ATP phosphate 
buffer 
incubation 
time 
DNA label 
160mM 1mM 25mM, pH 6.8 5min radioactive 
 
4.4 The XLID patient cell-line 106 has reduced MutYH glycosylase activity 
compared to the healthy individual  
Once the conditions for the glycosylase assay were established, the MutYH activity was 
compared between the XLID patient cells and cells from a healthy individual. When the 
glycosylase removes a misincorporated A opposite 8-oxo-G it leaves behind an AP site. In an 
experimental setup, the sugar backbone is then cleaved by the addition of NaOH, which 
causes a single-strand break formation and migration of labeled DNA substrate at a lower 
position under denaturing condition (Figure 19A). As the breakage of the sugar backbone by 
NaOH is unspecific, it can occur either before or after the phosphate residue at the 3'-end. 
This is also visible on the gel, as the product faintly separated into two narrow bands (Figure 
19B). 
In line with the down-regulated MutYH protein levels (Figure 16), the MutYH glycosylase 
activity is reduced in XLID 106 cell-line (Figure 19B and D). P83 on the other hand shows 
only minor changes in MutYH levels and no decrease in the activity was detected (Figure 19B 
and E). 444 is the XLID cell-line with an increase in MutYH protein levels compared to WT 
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(Figure 16) and similarly elevated MutYH activity is present (Figure 19B and C). Overall, the 
results of the functional analysis correlate well with the changes observed on the protein level. 
 
  
  
Figure 19. The XLID patient cell-line 106 has reduced MutYH glycosylase activity 
compared to the healthy individual.  
(A) Scheme of DNA glycosylase assay. Whole-cell extracts are incubated and MutYH 
glycosylase is allowed to work. After final cleavage by addition of NaOH, activity is 
analyzed and quantified. (B) Removal of misincorporated A by MutYH glycosylase with 
increasing amount of healthy individual (WT) or XLID patient (444, 106 or p83) WCEs. (C-
E) Quantification of MutYH activity present in WT and (C) 444, (D) 106 or (E) p83 WCEs, 
from three independently performed experiments as the one depicted in (B). Error bars 
indicate S.D., p-values **≤ 0.01. 
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4.5 XLID patient cells 444, 106 and p83 misincorporate more frequently 
dATP opposite 8-oxo-G than cells from the healthy individual 
To evaluate the ability of the XLID patient cells to accurately and efficiently bypass 8-oxo-G 
damage, the WCEs were tested in an in vitro DNA polymerase assay (Figure 20A). As a 
substrate, 1nt-gap DNA substrate containing 8-oxo-G damage opposite the gap was used. 
The Pols present in the WCE can either incorporate the faulty dATP or the correct dCTP 
opposite 8-oxo-G, followed by the extension step (Figure 20A).  
  
Figure 20. XLID patient cells 444, 106 and p83 misincorporate more frequently the 
wrong dATP opposite 8-oxo-G than cells from the healthy individual.  
(A) Polymerase incorporation scheme. Whole-cell extracts are incubated with dNTPs 
containing either dATP or dCTP. Products of different lengths are subsequently analyzed 
and quantified. (B) Incorporation of dATP and dCTP opposite 8-oxo-G at different final 
concentrations by the healthy individual (WT) or XLID (444, 106 or p83) WCEs. (C-E) 
Comparison of 8-oxo-G bypass activity between WT and (C) 444, (D) 106 or (E) p83 WCEs, 
from three independently performed experiments as the one depicted in (B). Error bars 
indicate S.D., p-values *≤ 0.05, **≤ 0.01. 
 
  45 
The XLID patient cell-lines 444, 106 and p83 incorporate more frequently dATP opposite 8-
oxo-G than the cells from the healthy individual (Figure 20B-E). The incorporation of accurate 
dCTP does not significantly differ between WT and XLID cell-lines (Figure 20B-E), and is 
only slightly reduced in the case of the 444 cell-line (Figure 20B and C). These findings are 
thus to a certain extent in line with data presented in Figure 16, suggesting that reduced Pol λ 
protein levels influence cellular ability to accurately and efficiently bypass 8-oxo-G damage. 
4.6 Virus transduction of lymphoblastoid cell-lines 
The goal of the virus-transduction was to stably knock-down Mule by using short-hairpin 
RNA (shRNA) methodology. To visualize the approximate extent of transduction-efficiency, 
the coding plasmid contained the gene for green fluorescent protein (GFP) in addition to 
information needed for synthesis of shRNA. After ten days of selection with puromycin, 
more than 50% of the cells were GFP positive, indirectly indicating that the transduction was 
efficient and that shRNA was expressed in targeted cells (Figure 21).   
  
 
 
Figure 21. Virus transduction is efficient in all for cell-lines.  
(A-D) Healthy individual (WT) and XLID patient (444, 106 and p83) cell-lines have 
successfully integrated the DNA construct, represented by occurrence of green fluorescent 
signal. 
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4.7 DNA glycosylase MutYH and DNA polymerase λ  levels after Mule 
knock-down  
The protein levels of the two important factors involved in repair of A:8-oxo-G mispairs, 
MutYH and Pol λ, are downregulated in XLID patient cells (Figure 16). To test whether 
reduction of Mule levels can result in restoration of MutYH and Pol λ levels, stable knock-
down experiments were performed. Immunoblot analysis showed that the efficiency of Mule 
knock-down greatly varied between the cell-lines and in some instances was not extremely 
efficient (Figure 22). This could be explained with the large size of Mule, which makes its 
knock-down challenging. The strongest effect could be seen in WT cells while it was the least 
effective in 106 cell-line. Analysis of MutYH and Pol λ protein levels revealed that reduction 
in Mule levels resulted in an increase of MutYH protein levels in 106 cell-line and over-
expression in WT and 444 (Figure 22B and C). Pol λ levels were rescued upon Mule knock-
down in 444 XLID cells while in WT cells reduction in Mule lead to Pol λ accumulation 
(Figure 22B and D). These findings support the idea that Mule directly regulates levels of BER 
proteins involved in A:8-oxo-G repair as well as that this regulation is misfunctional in XLID 
patient cells. 
 
  
 
 
Figure 22. Protein levels of Mule, MutYH and Pol λ after knock-down of Mule. 
(A) Immunoblot analysis of Mule protein levels upon knock-down of Mule in the healthy 
individual (WT) and the XLID patient (444, 106 and p83) cell-lines by shRNA. (B) Changes 
in MutYH and Pol λ levels detected by immunoblot analysis upon Mule knock-down.  
Values on graph do not represent values in the figure. (C-D) Quantification of changes in 
(C) MutYH and (D) Pol λ protein levels between control and knock-down of Mule from 
three independently performed experiments as the one in (B). Error bars indicate S.D., p-
values *≤ 0.05. 
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4.8 MutYH glycosylase activity after knock-down of Mule 
As demonstrated in Figure 19, the activity of MutYH glycosylase is reduced in cell-line 106 
together with the protein levels (Figure 16). Therefore, the rescue upon knock-down of Mule 
was especially interesting for this cell-line. MutYH in 106 cell-line showed only a mild 
increase on the protein level, compared to the non-silenced condition (Figure 22). This very 
small change was reflected in slightly elevated glycosylase activity to remove A opposite 8-
oxo-G in both WT and 106 cell-lines (Figure 23). 
  
 
 
Figure 23. MutYH glycosylase activity is increased in the cell-lines of the healthy 
individual and of XLID patient 106 upon knock-down of Mule. 
(A) Removal of misincorporated A by MutYH glycosylase with increasing amount of 
healthy individual (WT) or XLID patient 106 WCEs. Both conditions, non-silenced (shNs) 
and Mule knock-down (shMule) are displayed. (B) Quantification of MutYH activity present 
in WT and 106 WCEs, from four independently performed experiments as the one depicted 
in (A). Error bars indicate S.D. (C) Scheme for the rescue of MutYH activity to remove 
wrong A opposite 8-oxo-G after knock-down of Mule. 
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4.9 DNA polymerase λ  activity after knock-down of Mule 
As with the glycosylase assay, the cell-extracts after Mule knock-down were tested in 
polymerase assays. Since the biggest difference in fidelity was observed between WT and 444 
extracts (Figure 20 and 24A), the focus was on the impact of Mule knock-down in these two 
cell-lines. Comparison of incorrect dATP and correct dCTP incorporation indicated that 444 
cells upon Mule knock-down incorporated dCTP equally well as WT cells (Figure 24B). This 
is not the case for dATP, for which 444 cells were still more error-free. However the dATP 
incorporation by WT cells with knock-down Mule was much higher than observed 
previously (Figure 20 and 24A) and thus requires further investigation, before firm 
conclusions can be drawn. 
 
  
 
 
Figure 24. Incorporation of wrong dATP opposite 8-oxo-G in cell-line 444 upon knock-
down of Mule. 
(A) Incorporation of dATP and dCTP opposite 8-oxo-G at different final concentrations by 
the healthy individual (WT) or XLID patient 444 WCEs under non-silenced (shNs) and 
Mule knock-down (shMule) conditions. (B) Comparison of 8-oxo-G bypass activity 
between shNs and (C) shMule WT and 444 WCEs from the experiment depicted in (B). (D) 
Scheme for the rescue of Pol λ activity to incorporate correct dCTP opposite 8-oxo-G after 
knock-down of Mule. 
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5 Discussion 
In this thesis, immortalized lymphoblastoid cells were used to represent the conditions in 
XLID patients with mutations in the Mule gene. Neuronal cells might behave differently and 
also the complexity of an organ plays important roles in the preservation of health and onset 
of disease. However, the chosen setting allowed to test the effects of mutated Mule on 
oxidative DNA damage repair. Previous research showed that the point mutation of an Arg 
to a Cys in the HECT domain of Mule in patient cell-line 444 renders the protein hyperactive 
(Ferrari. E and Hübscher U., unpublished). The neutral amino acid Cys with pHi 5.05 and the 
ability to form thioester-bonds replaces the basic Arg with pHi 11.76 (Figure 15). These 
alterations might suffice for the structure to change in a way that the activity increases. In 106, 
the mutation site lies outside the HECT domain and might affect stability, binding to 
substrates and interaction partners or subcellular localization. To address those questions, in 
vitro analyses with the specific Mule mutations as well as in vivo observation of the cells' 
behavior would be necessary.  
The focus of this work lay on the efficiency of oxidative BER in XLID cells. A:8-oxo-G 
mispairs arise since many Pols preferentially incorporate inaccurate dATP opposite 8-oxo-G 
246,247. The accurate repair of these mispairs depends on MutYH and Pol λ 11,248. It was 
observed that amounts of MutYH and Pol λ in the three studied XLID patient cell-lines are 
lowered. The reduction takes place mainly on the protein level (Figure 16), as mRNA levels 
are predominantly unchanged between the cell-lines (Markkanen E. and Hübscher U., 
unpublished). Mule targets Pol λ and putatively MutYH for degradation, which we propose 
as the direct cause of the altered protein levels in the studied XLID cells. The differences 
between individual cell-lines likely trace back to the distinct Mule mutations and possible 
posttranslational modifications stabilizing the proteins 249 and regulating DNA damage 
response 250. Epigenetic modifications on the DNA could further even out genetic variations 
251-254. 
MutYH and Pol λ not only work in the same repair pathway but they are also functionally 
connected 39. Subcellular fractions were prepared to identify changes in the cytoplasm, 
nucleoplasm and soluble chromatin of MutYH and Pol λ between the studied cell-lines 
(Figure 17). The expectation was that a reduction of MutYH on the chromatin would cause an 
insufficient recruitment of Pol λ and thus disable efficient BER of 8-oxo-G. The pattern in the 
cytoplasmic and nucleoplasmic fraction is in line with what was found in WCEs (Figure 17C 
and D). On the chromatin, 444 shows intact levels of MutYH but a decrease of Pol λ, which 
most likely arises due to the lower overall Pol λ levels in this cell-line. In 106, there is also less 
MutYH on the chromatin so that not enough Pol λ can be recruited. On the clinical side, 106 
has the most pronounced disabilities. Maybe the shortage of MutYH on the chromosome, as 
only observed in this cell-line, is at least partially responsible for the degree of XLID. P83 
shares similarities with both the others even though the gravest changes could be expected as 
this cell-line carries a Mule duplication. To draw a quantitative graph over more experiments 
and make firm conclusions, repetitions have to follow. Moreover, analysis of mitochondrial 
fractions could provide insight into possible influences of mitochondria in the pathogenesis 
of XLID, as seen in other cognitive disabilities, peripheral neuropathie and myopathies 255. 
In the functional setting of DNA glycosylase and polymerase assays (Figures 19 and 20), the 
MutYH and Pol λ reduction results in a deficient repair of 8-oxo-G lesions. 106 cell-line fails to 
remove A opposite 8-oxo-G as well as incorporate correct dCTP at WT efficiency. The 
dysregulation in 444 cell-line could even have graver consequences, as the high activity of 
MutYH taking out misincorporated A is followed by a lack of Pol λ, thus boosting the 
continuous generation of A:8-oxo-G mispairs. This could enhance futile cycles, lead to 
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oxidized AP sites and eventually increased prevalence of SSBs 256. P83 again takes a position 
in between as MutYH activity is comparable to WT but then followed by inaccurate gap-
filling.  
An interesting observation concerns the activity of Pol λ. It preferentially incorporates dCTP 
over dATP opposite 8-oxo-G on gapped DNA by a factor of 750 to 1200 38, ratios that were not 
obtained in our experimental setup (Figure 20). Previous studies employed recombinant Pol λ, 
PCNA and RP-A, while here WCEs were used, containing many different factors potentially 
stimulating as well as inhibiting the reactions. Since other Pols, such as Pol β, are also active 
on the 8-oxo-G lesion and have a lower fidelity to incorporate dCTP, the higher dATP 
incorporation detected in XLID WCEs is potentially due to the activity of these proteins. 
Namely, when Pol λ is present in the cell it binds to the DNA containing 1nt-gap opposite 8-
oxo-G and prevents other Pols from acting on this lesion. The reduction in Pol λ levels in the 
XLID patients possibly results in lower abundance of this Pol at the damage site, which is 
when Pol β could take over. Finally, the negative influence of Mule on MutYH and Pol λ 
levels could be shown in a Mule knock-down experiment. Knock-down was not complete but 
nonetheless there was a tendency of rescue of MutYH and Pol λ protein levels (Figure 22). 
 
 
Figure 25. Interplay of mitochondria, oxidative damage and the proteasome in 
neurodegeneration.  
(From Barry Halliwell. (2006) Oxidative stress and neurodegeneration: Where are we 
now? Journal of Neurochemistry) 
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The functional impact for MutYH activity in 106 (Figure 23) and Pol λ in 444 (Figure 24) was 
slightly visible and should be subsequently confirmed in extracts from more efficient knock-
downs. Figure 25 presents the network of mechanisms in oxidation-related 
neurodegeneration, which might partially apply to the pathogenesis of Mule-dependent 
XLID. The deficient repair of oxidative DNA lesions by MutYH/Pol λ BER leads to persisting 
A:8-oxo-G mispairs with the risk of G:C→T:A mutations. Altered proteins, mitochondrial 
dysfunctions and finally apoptosis push the development and progression of 
neurodegenerative diseases 257. Stress response and neuroinflammation may further 
deteriorate the integrity of the delicate neuronal tissue 258,259.  
Accumulation or increased activity of Mule in the observed XLID patient cell-lines can have 
many additional influences. Besides the studied alterations in BER, other targets of the E3 
ubiquitin ligase might get out of control (Figure 26). Cell division cycle 6 (Cdc6) 260 and Mcl-1 
155 are important for mitosis and apoptosis. Mule targets them for degradation 157,240,261,262, 
which prevents the propagation of mutations but may trigger cell death. This could also 
occur during neurogenesis, which was found altered in various forms of XLID. Structural 
aspects such as the branched morphology of dendritic spines as well as functional properties 
of synapses would be limited by a lagging cell cycle 190. Altered ubiquitination of 
transcription factors c-Myc 151,263, N-Myc and Myc-interacting zinc finger protein 1 (Miz1) can 
dysregulate cell cycle control and checkoint activation 264. The Mule-dependent degradation 
of N-Myc in neuronal progenitor cells prompts the signal to exit cell cycle and start 
differentiation 229,230,265. Mule is indeed increased during brain development and disturbances 
could either lead the cells to insufficiently differentiate or do so too soon. Besides that, 
shortage in Myc proteins has been shown to lead to an exaggerated reaction after DNA 
damage and thereby cause neuronal death 263. 
Also histones on the DNA itself are modified by ubiquitination 266 and acetlyation 267, which 
gave rise to diseases and therapeutical substances such as histone deacetylase inhibitors 
(HDACis) 268. Interestingly, overexpression of histone deacetylase 2 (HDAC2) impairs 
synaptogenesis in the nervous system and inhibits p83 activation after DNA damage 269,270. 
Mule has a regulatory function in these processes by modifiying histones directly through 
ubiquitination and indirectly by degrading HDAC 251,271. If the activity or affinity of mutated 
Mule towards these substrates is changed in XLID patients, it can trouble gene transcription 
in general, DNA damage response through p53, or synaptogenesis.  
 
 
Figure 26. Involvement of Mule in various cellular functions.  
See text for more details. 
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Other than the involvement with proteins of DNA repair and cell cycle control, Mule 
ubiquitinates the transcription factor myogenic differentiation factor D (MyoD) and a 
receptor of the circadian network Rev-erbα 272,273. MyoD activates muscle specific genes and 
allows the progenitor cells to differentiate 274-276. The enactment of the myogenic program 
requires appropriate activation of the genes involved and also includes the maintenance of 
progenitor cells (satellite cells) important for muscle regeneration 277,278. In fact, patients 
suffering from Mule-associated XLID exhibit flaccid facial expression due to weak muscles 
and patient 106, even displays flexor deformities preventing him from walking 1. This could 
be caused by hampered muscle development due to excessive degradation of MyoD by Mule. 
Finally, it would be interesting to check the XLID cells for proteins involved in Mule 
regulation, such as USP7S. Hyperactive or increased levels of Mule could for example be 
compensated by a decrease in USP7S. Thereby, Mule would rather be degraded after auto-
ubiquitination and target its substrates to a lesser degree. Such mechanisms could also assist 
in the explanation why certain known Mule targets do not show a decrease in the studied 
XLID cell-lines. On the other side, changes in USP7S also affect the epigenetic regulator 
ubiquitin-like with PHD and RING finger domains 1 (UHRF1) and thus alter DNA damage 
response 279. Moreover, many other substrates of USP7 are involved in proliferation, cell cycle 
control, DNA repair and apoptosis 164,280-282. 
A lesser tolerance of oxidative stress in Mule-dependent XLID suggests the reduction of ROS 
production or the application of antioxidative agents as therapeutic options. Even though 
diseases related to oxidative stress present as very heterogeneous - all in etiology, pathology 
and symptomatology - common concepts might be useful for treatment 283-287. Dietary 
adjustments, such as a low-calory diet that is known to increase life expectancy in rats 288,289 
and change cognitive functions and neurodegeneration 290-295 could be applied to affect the 
production of ROS. An other debated mechanism of caloric restriction is the induction of ROS 
scavengers upon energy shortage 296. As the restriction necessary to observe the benefits lies 
high in the range of 20 to 25% 297, the aim is to identify food components with the greatest 
oxidative potential and reduce their intake selectively. The restriction of proteins in general 
and Met in particular seem to have the biggest positive impact on life span and disease 
development 298. Accumulation of Homocys, (a harmful product from the Met metabolism, 
has been related to various neurodegenerative diseases and supposedly decreases resistance 
towards oxidative stress 299. The degradation of Homocys requires several enzymes as folic 
acid, vitamin B6 and 12 300, the supplementation of which can have a beneficial impact on 
neuronal survival 301,302. Other ingredients in food can directly combat ROS. They basically 
include the components important in cellular antioxidative mechanisms: vitamin C, vitamin E, 
carotenoids, α-lipoic acid, glutathione and others 283,303. Furthermore, flavanoids, a group of 
antioxidative agents with the ability to act as metal chelators, feature exciting therapeutic 
potential 304,305. They were shown valuable in reducing oxidative stress in neuronal tissue in 
certain studies and more insight is necessary to pinpoint practical application considering 
efficient dosage and combinations 306-309. Further, an interesting new approach is to use 
cellular detection sensors of ROS and enhance their controlling system, which involves the 
so-called vitagens. Certain vitagens, such as heme-oxygenase 1 (HO-1) can be induced in 
brain cells by intake of spices like curcumin 310. Curcumin additionally contains a variety of 
polyphenolic molecules that prevent lipid peroxidation and protect from ROS. Also the non-
proteinogenic amino acid acetyl-L-carnitine (LAC) found in plants and animals has the ability 
to induce HO-1, improve mitochondrial functions, stabilize membranes and even enhance 
repair mechanisms 311-313. Its therapeutical value lies in the treatment of neurochemical 
abnormalities, ischemia, aging, neurotropathic pain and even restoring memory function in 
AD or decreasing oxidative stress in the brain 314-317.  
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Taken together, the essential merit of understanding disease mechanisms lies in finding 
therapeutical options, which might not be that far away.  
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6 Conclusion 
Increased oxidative stress is a known factor in the development as well as progression of 
various neurodegenerative diseases. Neurons with their high oxidative metabolism need a 
functional repair machinery to combat increased oxidative DNA damage. Since neurons are 
highly differentiated and do not have an active cell cycle, they are not replaced after their 
death. While cellular dysregulation in other organs may lead to cancer, degeneration is the 
most frequent outcome in the nervous system. BER is one pathway to repair non-bulky DNA 
lesions such as the oxidized base 8-oxo-G. Functional BER with MutYH and Pol λ is crucial to 
deal with A:8-oxo-G mispairs, which have a highly mutagenic potential for G:C→T:A 
transversions. Such mutations might cause problems in the nuclear as well as mitochondrial 
processes and disturb cellular functioning until apoptosis is the outcome. In conclusion, it 
was shown that XLID patients with mutations in the Mule gene, and subsequently decreased 
levels in MutYH and Pol λ indeed have a hampered repair of A:8-oxo-G (Figure 27). The mis-
regulated repair of A:8-oxo-G mispairs results in preservation of A at the position of C. 
Among others, this might contribute to the synthesis of aberrant proteins and the subsequent 
initiation of different cellular responses, resulting in improperly functioning neurons and 
potential neuronal death during development. It is therefore proposed that certain types of 
XLID potentially arise due to an impaired response of neurons to oxidative DNA damage. 
  
 
 
Figure 27. Model: interference of of 8-oxo-G DNA repair by Mule. 
(A) SP and LP-BER of 8-oxo-G and the targeting for proteasomal degradation of MutYH 
and Pol λ. (B) Mule leads to a decrease in glycosylase activity by potentially degrading 
MutYH. This results in preservation of A:8-oxo-G mispairs and if repair synthesis or even 
replication takes place at the site of this mispair, G:C→T:A transversion mutations arise. 
The degradation of Pol λ promotes misincorporation of dATP opposite 8-oxo-G, which is 
insufficiently removed. 
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Figure 2 Structure of 7,8-dihydro-8-oxoguanine (8-oxo-G) damage. 
Figure 3 Structures of 8-oxo-G containing base pairs. 
Figure 4 Repair of a damaged DNA base via SP-BER (A) and LP-BER (B). 
Figure 5 The major protective mechanisms against the oxidative DNA lesion 8-oxo-G. 
Figure 6 Functional domains of MutYH. 
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Figure 8 Model for the MutYH initiated LP-BER of 8-oxo-G, after misincorporation by the 
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Figure 15 Mutation sites 444, 106 and p83 duplication in Mule. 
Figure 16 Changes of Mule, MutYH and DNA polymerase λ levels in three XLID patient 
cell-lines compared to one healthy individual. 
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Figure 21 Virus transduction is efficient in all for cell-lines.  
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down of Mule. 
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Figure 27 Model: interference of 8-oxo-G DNA repair by Mule. 
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 phenotypes. 
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